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ABSTRACT
Maternal urinary metabolites (organic acids and steroids) in human
pregnancy were profiled by gas-chromatographic methods. Urine specimens
were collected from pregnant women at two time intervals in gestation
(12~-15~ weeks and 24~-27~ weeks). A group of nonpregnant women was also
investigated. The 24-hour urinary creatinine excretion was used as a check
of the completeness of urine collections. Urinary organic acids were
isolated by anion-exchange chromatography (DEAE-Sephadex A-25). Urinary
steroids and steroid conjugates were isolated by adsorption onto a neutral
resin (Amberlite XAD-2). Steroid conjugates were hydrolyzed by enzymes
from the digestive juice of the snail, HeZi~ pomatia. Purified urinary
organic acid and steroid extracts were methoximated and trimethylsilylated
for gas-chromatographic analysis. Urinary acid profiles contained 50
recognizable peaks, 10 of which were unequivocally identified by mass
spectral analysis (lactic acid, glycolic acid, sulfate, phosphate, erythronic
acid, threonic acid, hippuric acid, citric acid, glucuronic acid, and uric
acid). Urinary steroid profiles contained 16 recognizable, peaks, although
only one peak was identified by mass spectral analysis (pregnanediol).
The metabolite profiles were assessed for effects of diet, drugs,
and intestinal microflora. Twelve acidic metabolites were excreted in
greater amounts by pregnant women compared to nonpregnant women. Four
acidic metabolites were excreted in greatly increasing amounts as pregnancy
progressed: lactic acid, glycolic acid, the 4-deoxytetronic acids (only
tentatively identified), and erythronic acid. Whereas lactic acid excretion
was highly variable, the excretion of glycolic acid, the 4-deoxytetronic
acids, and erythronic acid increased simultaneously. ' The possible
significance of these alterations in the urinary acid profile in pregnancy
was discussed. Organic acid excretion in several cases of high-risk
pregnancy showed slight deviations from the normal profile.
Urinary steroid excretion increased consp~cuously as pregnancy
progressed. The steroid metabolites could not be accurately quantified
due to a lack of resolution with the present gas-chromatographic system.
The present method would prove useful when large deviations in steroid
excretion were to be confirmed.
Urinary organic acid-steroid profiling may not find application
in health assessment of the general population, but the technique holds
exciting possibilities for the assessment of certain high-risk pregnancies.
The present work provides reference profiles which form a basis for future
comparisons.
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1. INTRODUCTION
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Hemodynamic alterations (including increases in blood volume,
cardiac output, and renal blood flow) are established in the early weeks
of pregnancy (Hytten and Leitch, 1971). Such changes are anticipatory,
preparing the way for fetal demands at a later stage. Maternal fat
stores begin to increase early in gestation and reach a maximum in the
second trimester, providing an important caloric reserve for the
tripling of fetal weight over the last 13 weeks (Milley and Simmons, 1979).
Pregnancy is an overall anabolic state for both the mother and her fetus.
Maternal ability to store depot fat in early gestation, followed by the
mobilization of those stores in late gestation, has led to the concept
of an early anabolic phase followed by a later catabolic phase with respect
to maternal fuel disposition in pregnancy (Knopp et al., 1981). The
impaired effectiveness of maternal glucose removal from the circulation
in late pregnancy serves to maintain an adequate plasma glucose supply
to meet the obligate requirements of the fetus.
A general quiescence of metabolism in maternal tissues and
decreased muscle tonus are energy-saving adaptations of pregnancy (Hytten,
1972). This reduced tempo may reflect a reduction in the circulating
level of free thyroid hormone due to changes in thyroxine binding
(Hytten and Leitch, 1971; Burrow, 1977). Low vagal tone, hypomotility,
and decreased gastric secretion delay stomach emptying in pregnancy and
lead to a high incidence of nausea and heartburn (Hytten and Leitch,
1971).
An increased plasma concentration for several components of the
blood coagulation system produces the hypercoagulability of pregnancy
which protects against excessive blood loss (Cavanagh ~ a1., 197~). The
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plasma concentration of other substances (hemoglobin, iron, amino acids)
may decrease in pregnancy due to the increased plasma volume, but the
total circulating quantity of that substance may be increased (Lind, 1980).
The -lowering of nutrient levels in-the blood may favor transfer to the
fetal rather than maternal tissues (Hytten, 1972).
The pregnant body must preserve a new homeostasis which would
simulate pathology in the nonpregnant body. Clearly, new reference
standards of normality must be applied in the assessment of pregnancy
(Young et al., 1975). Failure to achieve the normal adaptive changes in
pregnancy may deny the fetus of an optimum environment during its 40-week
course of development.
1.1.2 Altered renal function
The kidneys of normal pregnant women probably enlarge during
gestation, and dilatation of the renal calyces, pelves, and ureters is
evident during the first trimester (Lindheimer and Katz, 1977). In the
human, approximately one-fifth of the total cardiac output traverses
the kidney (Lindheimer and Katz, 1977). One-third of the increased
cardiac output in pregnancy is distributed to the kidneys, raising renal
blood flow from a nonpregnant rate of 800 ml/min to a rate of 1200 ml/min
by the 9th week of gestation (Hytten and Leitch, 1971). Glomerular
filtration rate, a reflection of the renal plasma flow, is increased
during the first trimester of pregnancy and remains elevated until
delivery (Davison, 1974; Davison and Hytten, 1974; Dunlop, 1980).
Since the glomerular filtration rate increases without substantial
alterations in the production of creatinine, urea, and uric acid, renal
clearance of these solutes is increased (Lindheimer and Katz, 1977).
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In the normal nonpregnant state, nutrients passed by the renal
glomeruli are reabsorbed with great efficiency by the proximal tubules
(Hytten, 1973). In pregnancy, an upset in glomerulo-tubular balance
occurs, resulting in a tendency for substances which are reabsorbed in
the tubules to be excreted in greater amounts (Davison and Hytten, 1974).
Whether each glomerulus is delivering more filtrate to an unchanged
tubular system, or whether nephrons of low reabsorptive capacity are now
being perfused, the result is a variable partial failure of tubular
reabsorption. Almost all amino acids are excreted in greater amounts
during pregnancy (Hytten and Cheyne, 1972). During early pregnancy the
excretion of glycine, histidine, threonine, serine, and alanine doubles,
and by the end of pregnancy the losses increase to fivefold (more than
1 mmol per 24 h). A second group of amino acids (lysine, tyrosine, cystine,
taurine, leucine, phenylalanine, and valine) are excreted in greater
amounts during the first trimester, but the levels fall thereafter. The
remaining amino acids show little or no increase in excretion. The
pattern of aminoaciduria is not related to the chemical structure or
biological function of the amino acids (Hytten and Cheyne,-1972). Glucose
excretion is highly variable in pregnancy and may exceed 1 g in 24 h
(Hytten, 1973). The excretion of xylose, ribose, and fucose is significantly
elevated in the first trimester (Date, 1964a). Lactose excretion is
increased tenfold by the third trimester (Date, 1964a) 01igosacchar!de
excretion is also increased in pregnancy (Date, 1964b, 1964c), several
being pregnancy-specific. and detectable by thel3th week of pregnancy
(Hallgren et al., 1977; Hallgren and Lundblad, 1977a, 1977b). Water-
soluble vitamins are excreted in excess in pregnancy, the excretion of
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nicotinic acid and ascorbic acid being approximately doubled (Hytten, 1973).
Folate excretion increases two- to fourfold (Fleming, 1972; Landon and
Hytten, 1971). The excretion of vitamin B12 is also likely to increase
(Hytten' and Leitch, 1971). Urinary excretion of po1yamines is increased
in pregnancy (Russell and Durie, 1978; Russell et a1., 1978). Putrescine
and spermidine excretion is doubled, whereas spermine excretion may be
increased 75-fo1d (up to 5 mg per 24 hours).
The mechanisms of altered renal function may be hormonal. Hytten
and Cheyne (1972) discussed a pattern of aminoaciduria which was induced
in men by giving 100 mg of cortisol daily. These workers noted that the
similar aminoaciduria of pregnant women is apparent within the first two
months of pregnancy although there is no convincing evidence of increased
corticosteroid activity. Katz and Lindheimer (1977) reviewed the actions
of hormones on the kidney and noted the parallel increase of progesterone
levels and renal plasma flow during human gestation. They also cited
evidence that estrogens decrease the tubular reabsorption of ascorbic
acid in man. It is also possible that compression of large vessels
in the abdomen by the pregnant uterus, combined with urinary tract
dilatation, may alter renal function in pregnancy (Davison and Hytten,
1974).
The clinical consequences of altered renal function are substantial.
Urinary tract dilatation may lead to retention of large volumes of urin~,
introducing errors in the collection of timed urine samples (Lindheimer
and Katz, 1977). The bizarre wastage of nutrients in the urine may be
deleterious in areas of the world where vitamin and protein intake is
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marginal (Hytten, 1973). It is not known if the kidneys economize in
these circumstances of dietary inadequacy. The high nutrient content of
urine, combined with the tendency for stasis, increases the liability of
urinary tract infection in pregnancy (Hytten, 1976). The increased
renal clearance in pregnancy results in a more rapid elimination of
drugs (Dickason et al., 1978). This is a protective mechanism, since
nearly all drugs enter the fetal circulation following maternal administration
(Green et al., 1979) and may exert different effects upon the fetus
(Schardein, 1976).
1.1.3 Biochemical methods for monitoring risk pregnancies
Fetal growth in humans is affected by a variety of factors (Miller
and Merritt, 1979). Some of these factors, including maternal parity
and race, playa role in all pregnancies. MOst of the abnormal factors
affecting pregnancy are of the growth-retarding type. These include fetal
factors (chromosomal aberrations, congenital malformations, inborn
errors of metabolism), medical complications during pregnancy (acute
or chronic hypertension; severe chronic disease involving heart, liver,
lungs, kidneys, gastrointestinal tract, thyroid, or adrenal glands;
severe chronic infections; continuous medication with corticoids,
immunosuppressives, or growth-retarding drugs; abnormalities of the
uterus, placenta, or umbilical cord), maternal behavioral' conditions (lack
of prenatal care, dietary inadequacy, low prepregnancy weight for height,
age less than seventeen or more than thirty-five years, cigarette smoking
or use of addicting drugs or alcohol), and environmental factors (high
altitude, exposure to toxic substances, irradiation). A pregnancy
associated with these detrimental factors is described as high-risk due
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to the increased chance of problems developing for the mother or her
fetus (Hobel, 1976). Complications may lead to miscarriage, premature
birth, neonatal mortality, or neonatal morbidity (long-term physical,
neurological, mental, or immunological handicap). Thus, there is a
great need to monitor pregnancies for establishing risk.
Direct or indirect visualization of the fetus is possible through
roentgenography, amniography, fetography, ultrasonic scanning, or
fetoscopy (Burton et al., 1974). These methods can be used to detect
anatomic defects in utero. Sampling of fetal tissues can be accomplished
either directly or through aminocentesis followed by cultivation of amniotic
fluid cells. Cytogenetic study of fetal cells will confirm a chromosomal
abnormality, while appropriate enzyme assays on the amniotic fluid or
cultured fetal amniocytes may confirm a metabolic disease (Burton et al.,
1974). Various organic constituents of amniotic fluid may be assayed
to evaluate fetal maturity: creatinine, lecithin/sphingomyelin ratio,
total protein (Dito, 1980; Seeds, 1980), or cortisol .(Bjorkhem et al.,
1978; Dawood, 1977). Elevated amounts of certain metabolites in amniotic
fluid are associated with specific fetal conditions: alphafetoprotein
in neural-tube defects (Seppala and Ruos1ahti, 1976); methylma10nic
acid in methylmalonic aciduria (MOrrow ~ al., 1970; Nakamura et al., 1976);
methylcitric acid in methylma10nic aciduria (Naylor et al., 1980) or
propionic aciduria (Sweetman et al., 1979b); glutaric acid in glutar~c
aciduria (Goodman et al., 1980; Kvittingen et al., 1981); pyrog1utamic
acid in pyroglutamic aciduria (Larsson ~ al., 1974); argininosuccinic
acid in argininosuccinic aciduria (Goodman et al., 1973; Fleisher et al.,
1979); mucopolysaccharides in Hurler's syndrome (Matalon et a1., 1970);
-8-
17a-hydroxyprogesterone and pregnanetrio1 in congenital adrenal
hyperplasia due to 2l-hydroxylase deficiency (Jeffcoate et al., 1965;
Frasier et a1., 1975; Milunsky and Tulchinsky, 1977; Nagamani et al.,
1978); and tetrahydro-ll-deoxycortisol (tetrahydrosubstance S) in congenital
adrenal hyperplasia due to lIS-hydroxylase deficiency (RosIer et al.,
1979). Amniotic fluid dehydroepiandrosterone sulfate is elevated
four- to fivefold in placental sulfatase deficiency (Hahnel et al., 1982).
The foregoing techniques of visualization or amniocentesis must
be assessed in terms of the-risks to the mother and fetus --
radiation exposure, infection, or other unidentified consequences (Chard,
1974; Scrimgeour, 1978).' Amniocentesis should not be done before 13
weeks after the first day of the last menstruation due to technical
aspects and the risks involved (Lindsten et al., 1976). In contrast,
the collection of blood or urine specimens from the mother is virtually
without risk. A revolution in prenatal diagnosis may be forthcoming with
the recent isolation of fetal cells from maternal blood samples as
early as 15 weeks gestation (Iverson et al., 1981). With a fluorescence-
activated cell sorter these workers used antibodies to a paternal cell
surface antigen to select fetal cells from the lymphocyte fractions of
maternal blood samples. While cultivation of amniotic fluid cells
requires up to three weeks, only three days of culture are required with
the sorted fetal cells (Iverson et al., 1981).
In addition to cytological investigations, biochemical parameters
in maternal body fluids can be monitored by serial determinations.
Evaluation of a pregnancy is based on a combination of these parameters
and parallel physical examination. Hormones of the fetoplacental unit
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are the prevalent choice, although there is presently little definitive
knowledge regarding control of fetoplacental hormone production or the
precise role of these hormones. The status of an early complicated
pregnancy is best assessed by monitoring a placental hormone. The
placental proteins human chorionic gonadotropin (ReG) and human placental
lactogen (HPL) give prognostic validity until the 13th to 14th week
of gestation (Goebel, 1978). ReG is detectable in maternal serum and
urine 9 to 10 days after conception, maximal values being reached between
the 9th and 11th week of pregnancy (Keller, 1976b). RCG is important
for the maintenance of early pregnancy because of its luteotrophic
effect on the corpus luteum. The corpus luteum has a functional life of
about 10 weeks, its primary role being progesterone secretion to maintain
the early implanted blastocyst (Yoshimi et al., 1969). HPL, always
measured in blood due to its short half-life, is first detectable around
the 5th week of pregnancy. Levels rise to a peak a.t_ 36 weeks, thereafter
showing a plateau or slight decline (Letchworth, 1976). A multitude of
actions, including lactogenic, luteotrophic, and metabolic effects have
been attributed to HPL. Its levels are interpreted to reflect placental
function. If the production rates ofRCG or HPL are low or decreasing,
the likelihood of an unavoidable abortion is extremely great, whereas
rising values are a good prognosis (Goebel, 1978)~ The same is true for
levels of ovarian and placental steroid hormones (estrone, l7S-estradiol,
and progesterone) which are induced by RCG and HPL. The plasma level
of estrone and l7S-estradiol increases continuously during the first
9 weeks of pregnancy, followed by a more significant rise which is
maintained until term (Kunzig and Geiger, 1976). Serum progesterone
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(along with its excretory counterpart, urinary pregnanediol) rises
steadily from conception until the end of pregnancy (Keller, 1976a).
Highly specific and sensitive radioimmuno1ogica1 methods have been most
widely used for routine assays of ReG, HPL, plasma estrogens, and plasma
progesterone (Abraham, 1974).
The status of a late high-risk pregnancy is most often assessed
by monitoring the fetop1acental steroid estriol. Estriol is produced by
the placenta from the fetal adrenal precursor dehydroepiandrosterone
sulfate, and thus serves as an indicator of disorders in the fetal
compartment. The physiological function of estrogens is not well
understood but they appear to promote growth by influencing cell
proliferation and division, protein synthesis, and membrane stability
(Kunzig and Geiger, 1976; Be1ing, 1977). Estriol production shows a
pronounced increase only after the 12th week of gestation, due to the
secretory differentiation of the fetal adrenal (Ku~zig and Geiger, 1976).
During pregnancy the concentration of estriol in 24-hour urine shows a
IOOO-fold increase compared to the luteal phase of the menstrual cycle,
whereas the concentration of estrone and l7a-estradiol rises about 100-fold•.
Thus, the glucuronide conjugates of estriol comprise 90 to 95% of the
classical estrogens excreted in late pregnancy urine, often as much as
50 mg per 24 h (Beling, 1977). For this reason the total urinary
estrogen fraction is often equated with estriol and rapidly assayed ~y
colorimetric methods, avoiding complex procedures for conjugate
hydrolysis and resolution of components (Wolfrum, 1978). Reduced
concentrations of urinary total estrogens almost always reflect risk
situations in pregnancy and at birth (Goebel, 1978; Carlstrom and
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Lindberg, 1980). Roughly 90% of women with a growth-retarded baby have
estriol excretion below the normal range (Kunzig and Geiger, 1976).
Various other biochemical parameters have been studied for
surveillance of high-risk pregnancies. The major plasma protein of the
early human fetus, alphafetoprotein (AFP), has been used for the antenatal
detection of neura1~tube defects (anencephaly, spina bifida, and
hydrocephaly), disorders in the digestive system, and congenital nephrosis
(Goebel, 1978). Raised maternal serum AFP levels are usually associated
with these severe fetal disorders, although amniotic fluid levels may
be more reliable (Seppala and Ruos1ahti, 1976). Assays for maternal
serum enzymes of placental origin (oxytocinase, heat-stable alkaline
phosphatase) have failed to meet the criteria for a clinical placental
function test (Curzen, 1976). Recently it was proposed that metabolic
activities of maternal leukocytes may serve as markers of metabolic
changes in fetal cells (Mameesh et al., 1976; Crosby et al., 1977).
Leukocyte pyruvate kinase activity was reduced and some kinetic properties
of the enzyme were affected in mothers delivering fetally malnourished
babies (Mameesh et al., 1976). The authors suggested that the altered
response of this enzyme in fetal malnutrition could be due to an-
imbalance of nutrients and metabolites in the mother without overt
nutrient deficiency. This imbalance could affect susceptible enzymes in
critical pathways of energy metabolism, such as glycolysis, which are
necessary for the rapidly replicating fetal and placental cells or maternal
leukocytes. This metabolic approach to routine diagnosis has yet to be
applied. Other workers have focussed on steroid hormones such as
estetrol (15a-hydroxyestriol) which may be largely fetal in origin, but
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further investigations are needed to determine the reliability of this
parameter (Kunzig and Geiger, 1976; Klopper, 1977; Kundu et al., 1978).
Prenatal diagnosis of inborn errors of fetal metabolism through
biochemical monitoring of maternal urine is emerging as a reality in
specialized laboratories. The first such case, described by ~rrow et ale
(1970), involved the detection of elevated methylmalonic acid In the urine
of a mother carrying a fetus affected with methylmalonic aciduria.
Maternal urinary methylmalonate, quantitated by a colorimetric method,
was elevated after 25 weeks- of gestation. MOre recently, other
investigators have detected the same inborn error of metabolism in
utero by measuring an elevation in maternal urinary methylmalonate as
early as 16 weeks (Mahoney et al., 1975), 22 weeks (Bakker et al., 1978),
and 23 weeks (Nakamura et al., 1976). Congenital adrenal hyperplasia
can be diagnosed prenatally on the basis of elevated levels of
tetrahydrosubstance S (RosIer et al., 1979) and estriol (Cathro et a1.,
1969) in maternal urine. Placental sulfatase deficiency is reflected
by the increased maternal excretion of steroid monosulfate conjugates
of l6a-hydroxypregnenolone, l6a-hydroxydehydroepiandrosterone, and
androstenetriol (Taylor and Shackleton, 1979; Hahnel ~ al., 1982).
Not surprisingly, placental sulfatase deficiency and congenital adrenal
hypoplasia are accompanied by reduced maternal urinary estriol excretion
(Fliegner et al., 1972).
1.2 Urinary organic acids and steroids
The urine provides a unique reflection of body chemistry. Since
the kidney tubules do not effectively reabsorb some metabolites (for
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example, organic acids), the urine may contain higher concentrations
of those metabolites than does the plasma (Goodman, 1980). The
placental circulation may be capable of clearing any accumulation of
metabolite that occurs during fetal life, but the maternal urinary
excretion of that substance might provide a prenatal diagnosis
(Milunsky et al., 1970). Thus, urine may afford a means of examining
the fetus through the screen of the mother. Collection of urine is
simple, causing a minimum of inconvenience to the patient.
While the excretion of other classes of compounds in pregnancy
has been documented, little is known of organic acid excretion. The
urinary organic acids comprise a category of compounds which reflect
many important metabolic routes involving carbohydrates, amino acids,
lipids, amines, nucleic acids, and vitamins. The organic acids form a
heterogeneous class with many different functional groups (carboxyl,
hydroxyl, carbonyl, sulfhydryl, amino, imino) and a wide range of
structures (aliphatic, aromatic, imidazolic, indolic),(Nordmann and
Nordmann, 1961).
Analysis of organic acids in urine can provide an~asy, rapid
diagnosis for about 50 of the 180 known inborn errors of metabolism
(Tanaka and Hine, 1982; Watts, 1978; Jellum, 1977). In addition,
organic acidurias have been reported which are characteristic of
riboflavin deficiency (Goodman, 1981), biotin deficiency (Sweetman
et al., 1979a), vitamin B12 deficiency (Higginbottom et al., 1978),
vitamin B6 deficiency (Rose, 1972), as well as generalized insufficiency
due to the dietary neglect of alcoholism (Mamer et al., 1978).
Dicarboxylic acid excretion is a recognized response in patients with
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ketosis (Niwa et al., 1982b; Truscott et al., 1979b; Pettersen and
Stokke, 1973; Pettersen et al., 1972). Certain malignancies are
accompanied "by an increased excretion of vanilmandelic acid and
homovanillic acid (LaBrosse et al., 1980; Muskiet et al., 1977;
Addanki et al.,1976) or 5-hydroxyindole-3-acetic acid (Haverback
et al., 1956).
Much more is known of urinary steroid excretion than of
organic acid excretion. The urinary steroids form a more homo-
geneous group. All steroids have the basic cyclopentanoperhydro-
phenanthrene nucleus and differ only by theit functional groups
(hydroxyl, carbonyl), double bonds, or isomeric configurations.
Steroids are excreted in various conjugated forms (glucuronides,
sulfates, double conjugates) which add diversity to the metabolites
seen in the urine (Bernstein et al., 1970).
Urinary steroids can provide an index of adrenal, gonadal,
and fetoplacental function (Van der Molen et al., 1971) and thus
are of obvious importance in determining pregnancy status. In
addition, urinary steroids may reflect heritable defects in steroid
metabolism (Finkelstein and Shaefer, 1979).
1.3 Benefits, ~limita.tions, and objectives of the present study
Any antenatal screening procedure contributing to the prevention
of perinatal mortality or morbidity would prove highly cost-effective
in both humane and economic terms. Complications recognized prenatally
sometimes allow alterations to be made to the apparent course of
pregnancy. Adverse conditions recognized late in pregnancy may be
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curtailed by artificial induction of labor. Dietary therapy in utero
is advantageous in specific instances. For example, prenatal therapy
with vitamin BIZ in cases of vitamin-BIZ-responsive methy1malonic
aciduria is possible since vitamin BIZ crosses the placenta to accumu-
late in the fetus (Ampola ~ a1., 1975). The course of this prenatal
therapy has been monitored by analysis of multiple maternal urine
specimens which showed decreasing levels of methy1malonic acid as
therapy continued to term (Ampola et a1., 1975; Nakamura et al., 1976).
In fetal disorders diagnosed prenatally but not responsive to dietary
therapy in utero, treatment can be started immediately after birth.
The rapid postnatal deterioration associated with such conditions is
thereby averted. The application of new and existing biochemical
methods will increase the number of disorders detectable in utero, as
well as the potential for treatment of those disorders.
Investigations of human metabolism pose sp~cial problems
because genetic and environmental factors cannot be controlled. In
addition, the drastic changes in every maternal physiological system
during pregnancy would add to this heterogeneity. Current forms of
treatment (such as prophylactic use of iron, folic acid, and vitamins)
may modify the "natural" response to pregnancy (Hytten and Leitch, 1971).
Fetal outcome is often difficult to correlate with the prenatal
biochemical assessment. Subsequent complications in pregnancy or
birth-related trauma may disguise the original condition. In addition,
diverse complications are often grouped under one vague term. For
example, intrauterine growth retardation (Rosso and Winick, 1974; Jones
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and Battaglia, 1977) may have a variety of causes including maternal
malnutrition, abnormal placental function, genetic disposition, or
multiple combinations of these contributing factors. While retro-
spective evaluation of pregnancy relies mostly on evaluation of the
newborn, more attention could be paid to the physiology of the
placenta (Klopper, 1977).
Changes in maternal urinary metabolite excretion may reflect
the adaptations associated with normal human pregnancy (altered
renal function; emergence of sequential enzymatic pathways as the
fetus matures; alterations in metabolism due to the placenta). The
study of changes occurririg in normal pregnancy may help to explain
the etiology of unsuccessful pregnancies.
The objectives of the present study were:
1) the development of suitable profiling methods for organic acids
and steroids in biological fluids,
2) the application of those methods to 24-hour urine specimens from
reference groups of pregnant and nonpregnant women,
3) the identification of any alterations in metabolite excretion in
the course of normal pregnancy,
4) the comparison of metabolite excretion in high-risk pregnancies
to metabolite excretion in normal pregnancy.
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2. MATERIALS AND METHODS
2.1 Materials
2.1.1 Equipment and column materials
Equipment
Gas chromatograph (5730A)
Automatic sampler (7672A)
Integrator (3380A)
Vortex-evaporator
Temp-Blok module heater
Gas chromatography materials
Pyrex glass columns (coiled; 6 ft x 2 mm inside
diameter)
3% OV-lOl on 100/120 Gas Chrom Q
3% SE-30 on 100/120 Gas Chrom Q
MOlecular sieve 5A (60/80 mesh)
Low-bleed septa (Teflon-lined)
Column materials
Glass Econo-columns (20 em x 0.7 em)
DEAE-Sephadex A-25
Amberlite XAD-2
Amberlyst A-26
Supplier
Hewlett-Packard
Hewlett-Packard
Hewlett-Packard
Buchler
Pierce
Supplier
Supelco
Applied Science
Applied Science
. Hewlett-Packard
Supelco
Supplier
Bio-Rad
Pharmacia or Sigma
Sigma
Sigma
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2.1.2 Reagents, chemicals, and enzymes
Silylating reagents
N,O-Bis(trimethylsilyl)acetamide
N,O~Bis(trimethylsilyl)trifluoroacetamide
Dimethyldichlorosilane
N-Methyl-N-trimethylsilyltrifluoroacetamide
Sylon-CT
Trimethylchlorosilane
Trimethylsilylimidazole
Tri-sil "TBT"
Specialty solvents
Glass-distilled methanol
Glass-distilled hexane
Silylation grade pyridine
Chemicals and enzymes
Alkane standard kit
Ethoxyamine hydrochloride
Ethylmalonic acid
e-Glucuronidase, (Helix pomatiaJ
15u-Hydroxyestradiol
2-Hydroxyestriol
Methoxyamine hydrochloride
Methylsuccinic acid
All other biochemicals were obtained from Sigma.
Supplier
Pierce
Pierce
Pierce
Pierce
Pierce
Pierce
Pierce
Pierce
Supplier
BDH
BDH
Pierce
Supplier
Applied science
Eastman-Kodak
Aldrich
Sigma
Squibb
Squibb
Eastman-Kodak
Aldrich
Name and address of suppliers
Aldrich
Applied Science
BDH
Bio-Rad
Buchler
Eastman-Kodak
Hewlett-Packard
Pharmacia
Pierce
Sigma
Squibb
Supelco
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Aldrich Chemical Co. (Canada) Ltd.,
Montreal, Quebec
Applied Science Labs., Inc.,
State College, Pennsylvania
BDH Chemicals,
Terochem Laboratories Ltd.,
Edmonton, Alberta
Bio-Rad Laboratories,
Mississauga, Ontario
Buchler Instruments,
Fort Lee, New Jersey
Eastman-Kodak Co.,
Rochester, New York
Hewlett-Packard (Canada) Ltd.,
Edmonton, Alberta
Pharmacia (Canada),
Dorval, Quebec
Pierce Chemical Co.,
Rockford, Illinois
Sigma Chemical Co.,
St. Louis, Missouri
E. R. Squibb and Sons, Inc.,
Princeton, New Jersey
Supelco, Inc.,
Bellefonte, Pennsylvania
-20-
2.2 Sample collection
The project entitled "Early Diagnosis of Human Growth and Development
Disorders" was approved by the Principal's Advisory Committee on Ethics
in Human Experimentation (Appendix A). Informed consent forms (Appendix B)
were distributed to physicians in Saskatoon, who introduced the prenatal
study to obstetrical patients. Information on the completed consent
forms enabled us to contact the women regarding collection of samples.
Samples were collected during two time intervals in pregnancy according
to menstrual age (the number of weeks since the last menses began). The
first collection interval (12~ weeks to l5~ weeks gestation) was the
earliest time possible due to the delay dictated by the physician-patient
interaction. The second collection interval (24~ weeks to 27~ weeks
gestation) was followed by term and postpartum collections. In addition,
24-hour urine samples were collected from healthy nonpregnant women
between the 7th and 9th day of the menstrual cycle, with the requirement
that they were not using oral contraceptive agents.
Written instructions (Appendix C), which explained the protocol
for sample collection, were distributed to the participants. These
instructions were verbally reinforced at the time of collection, emphasizing
the need for a complete 24-hour urine collection and the necessity of
refrigerating or freezing the sample. The 24-hour urine collection began
in the morning, after rejection of the overnight specimen, and was
completed at exactly the same time the following morning. The urine
collection was made directly into a 2-litre polyethylene bottle using a
funnel. The time and quantity of food intake during the preceding 24 hours
was recorded by each patient as a diet recall (Appendix D). Food intake
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for the duration of the 24-hour collection period was recorded as a
diet diary (Appendix E). Other data recorded were height, present
weight, and drug status.
The total 24-hour urine volume was recorded. Aliquots in glass
screw-cap vials were frozen immediately since the urine was collected
without preservatives. Urine samples were collected from April 1979 to
January 1981 and stored at -30°C until required for analysis.
Medical information was extracted from prenatal records (Appendix F
and Appendix G) when the pregnancy terminated. These records contained
details of previous obstetrical history and the assessment of the present
pregnancy. The physicians categorized each pregnancy as either low-risk,
moderate-risk, or high-risk according to the calculated fetal risk score.
The infant discharge form (Appendix H) contained information on the
status of the newborn.
Patients selected to comprise the category of normal pregnancy
fulfilled certain criteria. These pregnancies were de.scribed as uneventful
and resulted in the delivery of a healthy newborn. Only those patients
with 24-hour urine collections taken in both time intervals during
gestation were considered. Several additional patients were selected
to comprise the category of high-risk pregnancy. Some of these pregnancies
resulted in the death of the fetus or neonate.
2.3 Creatinine determination
Urine was diluted lO-fo1d with distilled water and assayed in
duplicate by the method of Yatzidis (1974, 1975). The modified Jaffe
method of·Yatzidis measures the difference in absorbance at 500 nm of
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two alkaline picrate reagents. The color produced with pH 9.65 reagent
is due to protein only, whereas that with pH 11.50 reagent is due to
protein as well as creatinine. Other noncreatinine chromogens give a
measurable absorbance only with a more alkaline reagent (pH 12.00).
2.4 Extraction methods
2.4.1 Organic acid extraction
The DEAE-Sephadex A-25 anion exchange resin (new from the supplier
or previously used for organic acid extraction) was swollen in distilled
water for 24 hours. The swollen resin was washed on a medium porosity
fritted glass filter funnel successively with the following: 2.0 M
pyridinium acetate, 0.5 M hydrochloric acid, distilled water to neutrality,
0.5 M sodium hydroxide, and distilled water to neutrality (Mcquade et al.,
1981). The washed resin was stored in distilled water at 4°C until
poured as a slurry into glass columns (Bio-Rad Laboratories, Econo-
columns; 0.7 cm inside diameter) to a height of 8 ·em. The polyethylene
bed support in these columns allowed a reproducible flow rate (about 1 ml/min)
which facilitated the simultaneous operation of 20 columns. Each column
(bed volume, 3 ml; 0.5 g of dry Sephadex resin) was washed with 10 ml
of distilled water and 20 ml of 0.5 M pyridinium acetate immediately prior
to use (Chalmers and Watts, 1972c).
Each urine specimen or aqueous acid standard, previously stored
at -30°C in 10-ml glass vials, was thawed at room temperature and stIrred
to homogeneity with a small magnetic stirring bar. An aliquot of urine
calculated to contain approximately 1 mg of creatinine (0.50 to 2.00 ml)
was combined with 1.00 ml of aqueous glutaric acid or a-phenylpyruvic
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acid standard (200 llg/ml) in a 10 mm x 100 mm test tube. This mixture
was a.djusted to pH 7.5 with the addition of 0.25 ml of 1.0 M sodium
bicarbonate (Horrocks et al., 1976). This slightly basic sample was
appiied to the head of a prepared DEAE-Sephadex column and allowed to
drain in. Cations and neutral substances were eluted with 15 ml of
distilled water and discarded. The acidic metabolites were eluted with
two 10-ml volumes of 1.5 M pyridinium acetate into a So-ml Erlenmeyer
flask. Occasionally bubbles slowed the flow rate to less than 1 ml/min
but these were conveniently removed by gentle stirring with a glass rod.
The samples were frozen immediately at -aooc and later freeze-dried in
2o-sample batches for precisely 14 hours (freeze-drying chamber, room
temperature; condenser, -SOcCi vacuum, 0.3 Torr; vacuum pump, 150 l/min),
(Chalmers and Watts, 1972a). The dried residue in each flask was
transferred to a 10 mm x 100 mm screw-top test tube with three 1.0-ml volumes
of glass-distilled methanol (Dalgliesh. et al., 1966). The sample was
then evaporated to dryness in a vortex-evaporator after 70 min (Buchler
Instruments vortex-evaporator; heating block, 20°C; vacuum pump,
25 l/min). The purified acidic extract thus prepared was derivatized
for gas chromatography as described in the Methods, Section 2.5.
Figure 2.4.1 outlines the organic acid extraction method and indicates
the time required for each procedure. Twenty samples can easily be
processed in one day if the lengthy lyophilization step is allowed tg
proceed overnight.
Approximate time
required
(20-sample batch)
1 h
3 h
14 h
1 h
1 h
2 h
Total
time 22 h
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URINE
+
AQUEOUS ACID STANDARD
IAdjust to pH 7.5
t
DEAE-Sephadex A-25
(anion eX~Changer) WASH
. J..ater"'KBaSiC and neutral
compounds)
,
METHOX!ME-TRlMETHYLSILYL
DERIVATIVES
tGas chromatography
Figure 2.4.1 Outline of the organic acid extraction method,
indicating the time required for each procedure.
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2.4.2 Steroid extraction
The neutral resin Amberlite XAD-2 (60 g) was washed in succession
with 600 ml each of methanol, acetone, and water prior to being used
for- -the first time (Shackleton ~ al., 1970). Thereafter, the resin
can be used repeatedly for many years with only methanol and water
washes between each use (Bradlow, 1977; Leunissen and Thij ssen, 1978).
Resin fines were removed by a process of stirring and aspiration of the
supernatant. The Amberlite XAD-2 resin (2 g) was transferred to glass
columns (Bio-Rad Laboratories, Econo-columns witp a polyethylene bed
support; 0.7 cm inside diameter) which were used exclusively for steroid
extractions. These glass columns, other glassware, and glass pipettes
were previously silanized with 1% dimethyldichlorosilane (DMDCS) in
toluene to prevent loss of steroids due to creepage (Kushinsky and Anderson,
1974). Resin aggregates and air bubbles were dispersed by inverting the
column several times. Particles clinging to theg~ass were washed down
with water. Each column (0.7 cm x 8 cm) was washed with 30ml of
distilled water iIrimediately~heforeuse.
Each urine specimen or aqueous steroid conjugate standard,
previously stored at -30°C in glass vials, was thawed at room temperature
and stirred to homogeneity with a small magnetic stirring bar. An
aliquot of urine calculated to contain approximately 10 mg of creatinine
(5.0 to 20.0 ml) was combined with 2.00 ml of aqueous -androsterone
sulfate or 17~-estradiol-3~-D-glucuronide(200 ~g/ml) in a test tube.
This sample was applied to the head of a prepared XAD-2 column and allowed
to drain completely. Because of the low specific gravity of the resin
(1.03), a small amount of resin may float but this does not significantly
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impair conj ugate adsorption (Bradlow, 1968). The flow rate was kept
constant (0.5 to 1.0 ml/min) throughout the entire extraction procedure.
Faster flow rates affect the results only slightly (Osawa and Slaunwhite,
1970; Yapo et al., 1978). The columns were washed by pipetting two
--
10-ml volumes of distilled water onto the column, allowing the water to
drain completely between applications. Hydrophilic substances such as
glucose, urea, inorganic salts, amino acids, and low molecular weight
organic acids were eluted in these washes (Osawa and Slaunwhite, 1970).
The steroids were eluted with 12 m1 of glass-distilled methanol into
12.5 rom x 125 mm screw-top test tubes. Methanol and ethanol are equally
satisfactory eluents (Bradlow, 1968) but absolute alcohol tends to
precipitate pigmented urinary constituents and impair conjugate recovery
(MOore, 1972). ~e samples were evaporated to dryness in a vortex-
evaporator after 4 hours (Buchler Instruments vortex-evaporator; heating
block, 20°C; vacuum pump, 25 l/min). These dried residues were dissolved
in 2 m1 of acetate buffer (0.5 M acetic acid - 0.5 M sodium acetate,
pH 4.5). The digestive juice of Helix pomatia was then added (0.2 m1
of Sigma Type H-2 crude solution from Helix pomatia: a-glucuronidase
activity, 100,000 units/ml; also contains sulfatase activity). The test
tubes, sealed with teflon-lined screw caps, were incubated for 20 hours
at 37°C in a covered shaking water bath. The liberated steroids were
extracted by Amberlite XAD-2 as described above. The methanol eluates
from the XAD-2 columns were passed through Amber1yst A-26 anion exchange
columns to remove acidic impurities (Shackleton et al., 1970) only
when steroid extracts were to be combined with the DEAE-Sephadex
organic acid extracts. The methanol solutions were evaporated to dryness
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in the vortex-evaporator. The purified steroid extracts thus prepared
were derivatized for gas chromatography as described in the Methods,
Section 2.5. Figure 2.4.2 outlines the steroid extraction method and
indicates the time required for each procedure. Twenty samples can be
processed in two days if the lengthy enzymatic hydrolysis step is allowed
to proceed overnight.
2.5 Derivatization methods
2.5.1 Oximation
The keto groups present in keto acids and keto steroids were
converted to their oxime derivatives (Chalmers and Watts, 1972b).
Each oximating agent (methoxyamine hydrochloride, ethoxyamine hydrochloride,
or hydroxylamine hydrochloride) was dissolved in silylation grade pyridine
to form a saturated solution (1 g/50 ml), (Brooks and Harvey, 1970;
Sternowsky et al., 1973; Axelson, 1978). These oximating reagents were
stored at room temperature and remained chromatographically pure for many
months.
All organic acids, steroids, or steroid conjugates were of the
highest purity available from commercial sources and were used without
further purification. The compounds were dissolved in silylation grade
pyridine (1 mg/ml), (Sarkar and Malhotra, 1979), and stored at -30°C in
2-ml glass vials which were tightly capped with aluminum crimp-on
seals containing teflon-lined silicone septa. All steroids and steroid
conjugates were soluble in pyridine. ~st organic acids were pyridine-
soluble in their free acid form while most salts of acids (sodium, calcium,
barium, lithium, and potassium salts) were not pyridine-soluble. These
Approximate time
required
(20-sample batch)
2 h
4 h
20 h
2 h
1 h
4 h
2 h
Total
time 35 h
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URINE
+
AQUEOUS CONJUGATE STANDARD
I
Amberlite XAD-2
(noutra~:::e
Methanol
ELUTED STEROID CONJUGATES
vortex-e~orat1on
Enzymatic hydrolysis
tAmberlite XAD-2
(neutrtinlI Water
Methanol
I£LurED ;TEROIDSI·
Amberlyst A-26
(anion exchanger)
tVortex-evaporation
t
Derivatization
(Methoximation and
sUylation)
METHOX!ME-TRIMETHYLSILYL
DERIVATIVES
WASH
Hydrophilic
compounds}
WASH
Hydrophilic
compounds}
Gas chro tography
Figure 2.4.2 Outline of the steroid extraction method, indicating the
time required for each procedure.
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organic acid salts were converted to their free acid form and recovered
by DEAE-Sephadex anion-exchange extraction or ethyl acetate-diethyl ether
(solvent) extraction (Tanaka et al., 1980a, 1980b).
A suitable aliquot of a pyridine standard solution (containing
organic acids, steroids, or steroid conjugates - singly, and later in
suitable combinations selected according to retention times so as to
produce a series of peaks with no overlap) was transferred to a 10 rom x 100 mm
screw-top test tube. An equal aliquot of one of the oximating reagents
was added to this pyridine-solution. Likewise, an aliquot (250 ~l) of
an oximating reagent (usually methoxyamine hydrochloride iri pyridine)
·was added to the dried methanol residues obtained from urinary organic
acid or steroid extraction. The test tubes were tightly sealed with
teflon-lined screw caps and placed upright into a controlled-temperature
aluminum Temp-Blok module heater (Pierce Chemical Co.). The oximation
reaction was allowed to proceed for 75 min at 60°C (as determined in the
Results, Section 3.1.1).
2.5.2 Silylation
The reactive hydrogen atoms in the organic acids and steroids
(hydrogen atoms of hydroxyl, carboxyl, sulfhydryl, amino, and imino groups)
were replaced with silicon "atoms to which were attached methyl groups.
These trimethylsilyl derivatives can be produced by a variety of reagents
with different silylating abilities (Chambaz and Horning, 1969;
Gleispach, 1974; Nicholson, 1978). A mixture of N,O-bis(trimethylsilyl}-
trifluoroacetamide (BSTFA) and trimethylchlorosilane (TMCS) was chosen
for the silylation reaction for reasons outlined in the Results, Section 3.1.1.
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The BSTFA/TMCS reagent (5:l,v/v) was prepared immediately prior to use
from stock reagents previously stored at 4°C. An aliquot of the prepared
silylating reagent was added to the sample test ,tubes after completion
of the oximation reaction. A white precipitate of ammonium chloride was
often produced with this addition, ·butthat did not affect the reaction
or the chromatography (Dalgliesh et al., 1966; Nicholson, 1978),.
Subsequent heating of the silylation mixture at 60°C for 60 min dissolved
the ammonium chloride precipitate and resulted in a clear solution. The
volume of silylating reagent used always equalled the volume of pyridine
solution present for the oximation reaction (250 ~l for urinary organic
acid or steroid extracts)~ The test tubes were always tightly capped
during the silylation reaction to prevent evaporation.
The oximated-trimethylsilylated samples were cooled to room
temperature. An aliquot (100 ~l) of each sample was transferred with
a lOO-~l glass syringe to a 200-~1 cone-shaped glass vial containing 50 ~g
of tricosane. (A 50-~1 portion of a 1.0 mg/ml solution of tricosane in
hexane was previously evaporated undisturbed at room temperature over
a I-hour period.) The vials were tightly capped with aluminum crimp-on
seals containing teflon-lined silicone septa. A 2-~1 al~quot of each
sample was withdrawn for injection into the chromatograph. The sample
was injected into the gas chromatograph with the oven at an initial
temperature of 70°C (followed by a 4-min initial isothermal delay) and
the temperature was programmed to increase at 4°C/min to a final
temperature of 300°C.
Straight-chain hydrocarbons were coinjected with the derivatized
samples for the determination of methylene unit (MU) values (Dalgliesh.!! al.,
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1966). An aliquot of hexane containing 1 mg/ml of even-numbere~ (CIO to
C34) or odd-numbered (C9 toC27 ) n-alkanes was added to the sample vial
after all quantitative chromatographic runs were completed.
2.6 Gas-liquid chromatography
2.6.1 Chromatographic separation
2.6.1.1 Choice of column components
The wide range of column components available imparts versatility
to the technique of gas chromatography (GC). Conventional packed columns
were used exclusively, although capillary columns would have offered
improved separation of sample components (Cramers et al., 1971;
German and Horning, 1973). The chromatographic support chosen was
Gas-Chrom Q (Applied Science Laboratories, Technical Bulletin No.5:
Gas-Chrom Q consists of siliceous earth treated with sodium carbonate,
hydrochloric acid, potassium hydroxide, DMDCS in toluene, and methanol).
The 100/120 mesh range (125 ~m to 149 ~m) was chosen for highest column
efficiency (Ottenstein, 1973). From a wide variety of stationary
phases (Horning et al., 1963; Husek and Macek, 1975), the nonpolar
methylsilicones SE-30 and OV-lOl were chosen for their chemical and
thermal stability (Novotny and Zlatkis, 1971; MUeller et al., 1972;
Coleman, 1973). The stationary phase routinely used was OV-lOl
(Ohio Valley Specialty Chemical Co.), because of its fluid state which
results in increased efficiency at low temperatures (Trash, 1973).
The usual 3% loading of the stationary phase was used (Ottenstein, 1973).
The carrier gas, certified nitrogen (Canadian Liquid Air Ltd.),
was maintained at a flow rate of 25 ml/min through the columns (at 70°C).
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MOlecular sieve type SA traps (calcium aluminosilicate; crystal lattice
with pores ofS &ngstroms in diameter) were installed in the carrier gas
lines to remove moisture and other impurities. The molecular sieve was
outgassed at a temperature of at least 200°C (for periods up to 8 hours)
before installing the traps in the nitrogen lines. This action of heat
was necessary to d~ive off the water of crystallization of the sieve
to obtain a network of remaining empty holes (Bhatnagar, 1967). Failure
to properly outgas the molecular sieve had little effect on the chromatography
of standard solutions or the urinary steroid fraction, but completely
destroyed the ability to chromatograph the urinary organic acid fraction.
Urinary organic acid profiles obtained in this situation were identical
to chromatograms with severe peak tailing which were published by Thompson
(1977), and described ~y Chalmers et al.(1977) as an "occasional problem
on one type of Ge." These workers attributed the problem to column
deterioration caused by the deposition of incomp1et~ly derivatized urinary
sulfate and phosphate at the injector end of the column. Many hours
were spent troubleshooting this problem. The impurities driven off of the
molecular sieve (probably water, possibly calcium ions) irreversibly
contaminated the column packing. It is possible that these impurities
interacted with the urinary acid fraction to produce the smeared
chromatograms. The problem ~as not further investigated once the source
was identified and the molecular sieve properly outgassed. The seriousness
of this problem emphasized the sensitivity of the GC column to chemical
contamination.
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2.6.1.2 Column packing and conditioning
Signs of failing column performance (peak tailing, shortened
peak retention times, poor resolution of components, a rise in the base
line, extraneous peaks) indicated that the columns should be repacked.
AS'the columns aged, more active sites were exposed, rendering the
stationary phase more polar. A column could normally be used for some
250 urinary samples before signs of deterioration were observed.
Pyrex glass coiled columns (6 ft x 2 rom inside diameter, 0.25 inch
outside diameter) were base-washed and silanized according to the method
of Leibrand and Dunham (1973). The glass was treated successively with
1% aqueous potassium hydroxide, methanol, toluene, Sylon-CT, toluene,
methanol, and finally dried thoroughly in a stream of nitrogen.
Silanization reduced the hydrophilic nature of the glass and helped to
prevent adsorption of derivatives (Axelson, 1977; Rutten and L~yten
1972).
A glass wool plug (silanized glass wool) was inserted 1 em into
the detector end of the column. The empty column was. weighed and then
connected at the detector end to the suction of a water vacuum with
intervening water trap. The column packing (3% QV-101 on 100/120 Gas-
Chrom Q) was poured evenly into the injector end of the column through
an attached funnel. Gentle tapping with a pencil was maintained until
no further settling of the packing was noted. The column was again
weighed and finally plugged at the injector end with silanized glas~
wool. (The glass wool plug was inserted 3 cm into the injection end of
the column, allowing the injection syringe to deposit the sample just
above the column packing.) The 6 ft x 2 rom columns held 1.9 - 2.2 g of
packing.
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The packed columns were returned to the GC oven (Hewlett-Packard,
Model 5730A) and connected at their inlet end only. Nitrogen flow was
restored to 25 ml/min and the outlet end of each column was capped to
prevent backflow of air. The columns were conditioned at 500 e for 1 hour,
and then heated at a rate of 2°e/min to an overnight temperature of 320 0 e
(Walker et al., 1977). The upper temperature limit of OV-101 is 350°C.
Once conditioned, the injection port and detector ends of the
column were installed using graphite ferrules. The entire system was
I
carefully leak tested to ensure freedom from carrier gas leakage and
possible sample loss. Only teflon-coated silicone rubber septa
(Microsep F-174, Supelco) were used in the injection port (temperature,
250°C). The use of these low-bleed septa minimized the occurrence of
unexpected peaks which frequently arise from other septa. With less
inert septa the bleeding of si10xane polymers will occur at high
temperatures and appear as families of peaks resembling members of a
homologous series of compounds (Smith and Sorrells, 1971).
Samples were injected onto the column with an automatic sampler
(Hewlett-Packard, Model 7672A). The 10-~1 glass syringe w.s automatically
washed with hexane between samples. A thorough manual cleaning of syringes
with potassium hydroxide, water, acetone, and chloroform was a daily
routine (Walker et al., 1977).
2.6.2 Chromatographic detection
2.6.2.1 Flame ionization detection
Routine analyses were performed using a Hewlett-Packard, MOdel
5730A gas chromatograph equipped with dual glass columns and dual flame
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ionization detectors (FID). The detectors were operated in the differential
mode (base line compensation), resulting in negligible base line rise
with increase in temperature. TheFID response was recorded by a
Hewlett-Packard, MOdel 3380A reporting integrator. This instrument
plots a chromatogram with the retention time printed at each peak apex
(Healy et al., 1973). At the end of the run a report is printed which
tabulates retention times and peak areas for a maximum of 54 peaks in one
analysis. The integration cycle was initiated by the automatic sampler
on injection of the sample and was stopped by the sampler after a preset
time interval (usually 60 min). Peaks due to solvents and other reagents
occurring before 4.0 min were traced out but not integrated. This was
accomplished by use of- the integrate "delay" control. Likewise, the
use of the "area reject" control automatically rejected small peaks of
a selected area (less than 1,000 area counts for urinary samples). The
3380A has.a variety of integration capabilities: dropline allocation
separates merged peaks; peaks on the tail of a solven~ peak or other
severely tailing peak are tangent-skimmed for more accurate area measurement
(Cattran, 1975). The integrator was operated at an amplification of
10 x 16 (electrometer range x integrator attenuation), 0.5 ~g of a
straight-chain hydrocarbon giving a full-scale peak (approximately 200,000
area counts). Chart speed was 0.5 em/min.
The individual FlD is relatively insensitive to operating variables
such as gas flow rates near the optimum values (Giuffrida, 1971) or
detector temperature (Gill and Hartmann, 1967). In all analyses the
detector was maintained at 300°C. Hydrogen flow rate was 30 ml/min
(15 psi at the regulator) while the air flow rate was 250 ml/Ddn
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(25 psi at the regulator).
Bleed from the silicone gum rubber columns (Poulson and Jensen,
1971) and excess reagents used to make sily1. derivatives (Giuffrida,
1971) are combusted to produce deposits of silicon dioxide on the FID
collector electrodes (Lakeland and McDermott, 1968). These deposits
were removed by manually cleaning the flame jets and collector electrodes
(Walker et al., 1977) with 50% methanol/50% acetone after every 48 hours of
FID operation. The reassembled detectors were purged for 1 hour at
4000e with nitrogen and air-flow. The FID temperature was returned to
3000e and equilibrated before resumption of quantitative gas chromatography.
2.6.2.2 Mass spectrometry
The mass spectral analyses were performed by Dr. D. A. Durden of
the Psychiatric Research Division, University Hospital, Saskatoon. The
gas chromatographic separation used a conventional packed column as
before (glass coil, 6 ft x 2 rom inside diameter; 3% OV-101 on 100/120
mesh Gas-Chrom Q) with helium as the carrier gas (30 ml/min). The 2-pl
sample was injected into the GC with the oven at an initial temperature
of 1000e (followed by an 8-min initial isothermal delay) and the
temperature was programmed to increase at 4°e/min to a final temperature
of 300o e. A jet separator (De Brauw, 1979) allowed the Ge effluent to
enter the mass spectrometer (Vacuum Generators Micromass, MOdel 7070F).
The acquisition of mass spectral data was delayed for 4 min so as to-
vent off the solvent peak and avoid contamination of the ion source. The
mass spectrometer was operated in the electron impact ionization mode.
The mass spectrometry conditions were: ionizing voltage, 70 eV; source
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-5block temperature, 250°C; source p~essure, 10 . Torr; accelerating
voltage, 3 kV.
The mass spectrometer response was recorded by a Vacuum Generators
Multi Spec data system. Automatic repetitive scanning of the mass range
mle 20-700 was completed in 3.0 sec. Complete spectra of all component
peaks were accumulated on file. The computer system assigned mass values
to each ion peak in the spectra, ~subtracted background where necessary,
and presented normalized spectra graphically. The spectra were inspected
individually and those of special interest were printed to form a perma-
nent record.
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3. RESULTS
3.1 Gas-liquid chromatography
3.1.1 Oximating agents and silyl donors
Three oximating agents (hydrochlorides of methoxyamine, ethoxyamine,
and hydroxylamine) were chromatographed with a silylating reagent as
shown in Figure 3.1.1.1, B to D. The chromatographic profiles of
methoxyamine and ethoxyamine showed few peaks in addition to the solvent
peak. Hydroxylamine was silylated to form the oxime-trimethylsilyl
derivative which eluted at 10 minutes (Jakobs et al., 1977; Marner et al.,
1980). Additional silyl donors were chromatographed as shown in
Figure 3.1.1.1, E to H. The name, abbreviation, and structure of each
silyl donor is given in Table 3.1.1. BSTFA, alone or with the added
catalyst TMCS, produced a narrow solvent peak. BSA and its by-products
were less volatile than the fluorinated BSTFA as was seen by the wider
solvent front. TheBSA contained several additional peaks which
increased in size after prolonged storage and exposure to moisture
(Margosis, 1974; Munro et al., 1979). MSTFA showed several extra
peaks despite the manufacturer's claim that it is the most volatile
trimethylsilyl-amide available. TSIM obscured a large portion of the
chromatogram. While Tri-sil nTBT" is a silylating mixture specially
formulated for steroids, the large peak due to TSIM would hinder
chromatographic analysis of organic acids.
Thus, the combination of reagents producing the minimum of peaks
was seen to be methoxyamine or ethoxyamine hydrochloride in pyridine
with BSTFA and TMCS. This combination of reagents has several advantages.
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Figure 3.1.1.1 Cas-chromatographic profiles of oxtmatlng sgents and ailyl donora. All profiles represent 2-~1 injections and temperatura-programmed
operation (70· to 300·C at 4·C/min with a 4-.in initial isother-al delay) on 3% OV-l0l atationary phase. The systematic name, abbreviation, and
atructure of each ailyl donor ia given in Table 3.1.1.1. The reagents are: (Al BSTFA and THeS at 5:1 by volume, (B) 2% methoxyamine hydrochloride in
pyridine with an equal volume of A. (C) 2% ethoxyamine hydrochloride in pyridine with an equal volume of A, (D) 2% hydroxylamine hydrochloride in pyridine
with an equal volume of A. (E) BSA, (F) HSTPA, (G) TSIN, (n) Tri-al1 "TBT" (TSlN. BSA. mcs at 3:3:2 by volume).
Table 3.1.1 Systematic name, abbreviation, and structure of the silyl donors.
Systematic name Abbreviation Structure
~i(CH3)3
0
I
N,O-Bis(trimethylsilyl) acetamide BSA H3C-C=N-Si (CH3)3
~i(CH3)3
0
IN,O-Bis(trimethylsilyl)trifluoroacetamide BSTFA FaC-C=N-Si(CHa)a
I
+:--
0
~ "CH3 IF. C-C-NN-Methyl-N-trimethylsilyltrifluoroacetamide MSTFA a 'Si(CHa)a
yHa
H C-Si-CI
Trimethylchlorosilane TMCS a ICHa
~i(CHa)a
Trimethylsilylimidazole TSIM NlC.)
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Pyridine is a silylation catalyst, acting as an acid acceptor in the TMCS
reaction (Pierce, 1968) as well as having excellent solvent properties.
TMCS, water, and acids are all catalysts for the silylation reaction
(Chambaz and Horning, 1969). Thus, amine hydrochlorides increase the
rapidity of silylation (Van de Calseyde et al., 1972) and also enable
the silylation of sodium salts of certain organic acids (Poole et al.,
1976). The methoxime-trimethylsilyl (MO-TMS) system was chosen for
routine analyses because mass spectral data is plentiful for this
derivative.
The methoximation of dehydroepiandrosterone (DHEA) at three
different temperatures was followed as shown in Figure 3.1.1.2. The
disappearance of the DHEA-TMS peak paralleled the appearance of the MD-
DHEA-TMS peak. The reaction was complete after 30 min at 60°C. To ensure
complete methoximation of all keto compounds in urinary samples,
methoximation was allowed to proceed for 75 min at 60°C. Labile keto
acids (especially glyoxylic acid and oxalacetic acid) may decompose at
elevated temperatures (Lohr and Warren, 1962; Andersson et al., 1973)
and should be investigated individually if they are of special interest.
3.1.2 Retention data
Each compound was analyzed separately as its methoxime-trimethylsilyl
(MO-TMS) derivative to check for chromatographic purity. (It was soon
observed that all glassware must be carefully washed in chromic acid and
thoroughly rinsed in distilled water to avoid spurious peaks.) Maleic
acid chromatographed as two peaks, corresponding to maleic acid and
fumaric acid (approximately 1:1), possibly indicating an interconversion of
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Figure 3.1.1.2 Relative weight response of dehydroe~iandrosterone (DHEA) _
trimethylsilyl derivatives as a function of methoximation time and
methoximation temperature. Addition of silylating reagents at the
indicated times halted the methoximation reaction. The weight response
is relative to the internal standard tricosane. Each point represents an
average of two determinations.
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the cis- and trans- isomeric forms. a-Glycerophosphate and a-glycero-
phosphate had slight cross-contamination (about 5%) confirming the supplier's
claim of 95--99% purity. a--Hydroxybutyric acid in the free acid form (as a
liquid) had several contaminants. Pyruvic acid (Von Korff, 1969)
and lactic acid (Lockwood et al., 1965) have a reported tendency to form
dimers but were always chromatographed as single peaks. Oxalacetic
acid chromatographed as pyruvic acid but due to its unstable nature
(Bachelard, 1965) spontaneous decarboxylation would not be surprising.
The acylglycines hippuric acid and o-hydroxyhippuric acid (salicyluric
acid) chromatographed as their mono- and di-TMS derivatives respectively.
This formation of single derivatives for acylglycines agrees with results
by O'Neill-Rowley and Gerritsen (1975) but is in contrast with the two
derivatives formed by Ramsdell and Tanaka (1980). The aldonic acids
(gluconic, galactonic, and ribonic acid) each formed two peaks
corresponding to the free acid and its lactone (Kringstad and Bakke, 1977).
Uric acid (as the free acid) and salts of several acids (glucaric acid
calcium salt, glyceric acid hend-calcium salt,isoci.tric acid trisodium
salt, phthalic acid potassium salt, indoxyl sulfate pota~sium salt) did
not give any peaks by the direct derivatization process. This was probably
due to poor solubility and difficult silylation associated with certain
salts of organic acids (Poole et al., 1976). All of these acids were
detected after the anion-exchange isolation from aqueous solution w~ich
produced their pyridinium salts. These weakly ionic salts dissoclate
easily, allowing silylation to proceed more readily (Chalmers and Watts,
1972a) •
All steroids investigated eluted as single peaks when chromatographed
as their MO-TMS derivatives. In contrast, direct derivatization of steroid
-44-
glucuronide conjugates did not produce any response on the chromatogram.
Methyl ester-trimethylsilyl ethers (Horning et al., 1967; Jaakonmaki et al.,
1967b; VandenHeuvel, 1967) and propyl ester-trimethylsilyl ethers
(Miyazaki et al., 1976) of steroid glucuronides have been reported as
chromatographed and may be more stable than the present per(trimethy1sily1)
derivatives (Billets et al., 1973). Steroid sulfate conjugates investigated
(dehydroepiandrosterone sulfate and estrone 3-su1fate) chromatographed
as the MO-TMS derivatives of the free steroids (dehydroepiandrosterone
and estrone, respectively).- Apparently an acid-catalyzed hydrolysis of
the steroid sulfates resulted in the expulsion of S03 and consequent
derivatization of the unconjugated steroid (Murray and Baillie, 1979).
For inter- and intra1aboratory comparisons, the GC retention data
were expressed as methylene unit (MU) values. The MU value is equal to
the retention index of Kovats (1958) divided by 100. The MU value of a
derivative describes its elution characteristics relative to the
appropriate pair of flanking n-alkanes which differ by not more than two
carbon atoms (Dalgliesh et al., 1966). The MU value for a given compound
rarely varied more than 0.02. Slight deviations in temperature at the
start of the GC run occasionally produced variations of up to 0.04 for
compounds with MU values smaller than 13.00. The reproducibility of the
temperature program was generally good, absolute retention times usually
being within + 20 sec of the average retention time over a prolonged_
period of analysis. When mixtures of the compounds were chromatographed,
it was observed that a difference in MU value of 0.10 or more was needed
for complete resolution of components. Differences of 0.05 to 0.10 produced
twin peaks or shoulders, while compounds differing by less than 0.05
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emerged as a single peak. When a large amount of a compound (more than
2 ~g) was injected, the MIT value was slightly increased. The excess amount
caused a delay in peak retention time since that parameter was reported
at the peak apex.
The Mil values for MO-TMS derivatives of organic acids and steroids
are given in Tables 3.1.2.1 and 3.1.2.2 respectively. The nonpolar
stationary phase OV-lOl has an affinity for nonpolar compounds and tends
to separate components on the basis of their molecular size and shape.
The acids of low mo17cu1ar weight eluted with MU values between 10.04
(tig1ic acid - monoTMS, MW 172) and 18.00 (hippuric acid - monoTMS, MW 251).
The acids of higher molecular weight were retained longer, having MU values
as high as 24.54 (biotin - monoTMS, MW 316). The steroids formed a more
homogeneous group, eluting between MU 25.28 (androsterone-M:>-monoTMS, MW 391)
and MU 32.72 (cortisol-MO-triTMS, MW 636). Predictable relationships
were evident for the MU values of members of a homologous series, for
example the dicarboxy1ic acid - diTMS derivatives: o~alic acid, 11.26;
malonic acid, 12.02; succinic acid, 13.12; glutaric acid, 14.00;
adipic acid, 15.03; pimelic acid, 16.00; suberic acid, 16.93; azelaic
acid, 17.99; sebacic acid, 18.89; undecanedioic acid, 19.88. Other authors
have compiled comparable lists of MU v~lues for TMS derivatives of organic
acids (Butts, 1972; Petersson, 1977; Tanaka and Hine, 1982), inorganic
anions (Butts and Rainey, 1971), and steroids (Luyten and Rutten, 1974;
Pfaffenberger and Horning, 1977; Tomsova et a1., 1980).
A more extensive analysis of the keto groups was made to aid in
identification of keto compounds. The MU values for oxime trimethylsily1
derivatives of keto acids are listed in Table 3.1.2.3. When chromatographed
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Table 3.1.2.1 Methylene unit values for methoxime trimethy1si1y1
derivatives of organic acids.
Gas-chromatographic analyses were performed on a 6-ft packed
column containing 3% OV-101 on 100/120 mesh Gas Chrom Q.
* Indicates an acid with a carbonyl group which forms the methoxime
derivative.
§ cis - Oxa1acetic acid is decarboxy1ated to yield pyruvic acid.
• •••• continued
MU value
10.04
10.36
10.36
10.63
10.70
10.74
10.93
11.16
11.26
11.34
11.48
11.67
11.70
11.74
12.02
12.12
12.15
12.27
12.35
12.47
12.54
12.63
12.69
12.76
12.84
12.90
12.99
13.00 .
Organic acid
Tig1ic acid
Pyruvic acid*
cis-Oxa1acetic acid*§
Lactic acid
a-Hydroxyisobutyric acid
Glycolic acid
a-Ketobutyric acid*
a-Furoic acid
Oxalic acid
a-Hydroxybutyric acid
Sulfate
~-Hydroxybutyric acid
a-Ketova1eric acid*
a-Hydroxyisova1eric acid
Malonic acid
a-Ketoisocaproic acid*
Methy1ma1onic acid
Benzoic acid
Levu1inic acid*
a-Hydroxyisocaproic acid
a-Hydroxy-~-methy1va1ericacid
Caprylic acid
Nicotinic acid
Phenylacetic acid
Ethy1malonic acid
Phosphate
Maleic acid
Picolinic acid
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Table 3.1.2.1 (continued)
MU value
13.12
13.~9
13.48
13.53
13.54
13.65
14.00
14.34
14.37
14.55
14.72
14.89
15.01
15.03
15.07
15.07
15.07
15.18
15.47
15.57
15.58
15.63
15.76
15.78
15.85
15.94
15.96
16.00
16.12
16.14
16.18
16.25
Organic acid
Succinic acid
Methylsuccinic acid
Glyceric acid
Pyrrole-2-carboxylic acid
Fumaric acid
Pipeco1ic acid
Glutaric acid
a-Keto-y-methiolbutyric acid*
3,3-Dimethylg1utaric acid
Capric acid
Mandelic acid
Citramalic acid
Salicylic acid
Adipic acid
Acetopyruvic acid*
Malic acid
Pyroglutamic acid
trans-Cinnamic acid
3-Methyladipic acid
o-Hydroxyphenylacetic acid
m-Hydroxybenzoic acid
e-Pheny1pyruvic acid*
a-Ketoglutaric acid*
e-Phenyllactic acid
Tropic acid
a-Hydroxyglutaric acid
m-Hydroxyphenylacetic acid
Pimelic acid
meso~Tartaric acid
Anthranilic acid
p-Hydroxybenzoic acid
a-Hydroxy-e-methylglutaric acid
••••• continued
Table 3.1.2.1 ~ontinued)
MU value
16.26
16.35
16.43
16.49
16.58
16.69
16.75
16.82
16.84
16.93
16.93
16.95
17.17
17.51
17.52
17.56
17.56
17.62
17.82
17.87
17.92
17.99
18.00
18.20
18.23
18.29
18.40
18.44
18.48
18.50
18.50
18.51
18.78
18.87
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Organic acid
p-Hydroxypheny1acetic acid
a-Aminoadipic acid
Imidazo1eacetic acid
Lauric acid
a-Ketoadipic acid*
Tartaric acid
Phthalic acid
Veratric acid
Homoveratric acid
3-Indoxylsulfuric acid
Suberic acid
Ribonic acid y-lactone
Quino1inic acid
Vanillic acid
Orotic acid
Homovani11ic acid
a-Glycerophosphoric acid
cis-Aconitic acid
Gentisic acid
p-Hydroxymandelic acid
a-Glycerophosphoric acid
Azelaic acid
Hippuric acid"
Ribonic acid
3,4-Dihydroxybenzoic acid
3,4-Dihydroxyphenylacetic acid
Homogentisic acid
Shikimic acid
Myristic acid
Citric acid
Isocitric acid
Nicotinuric acid
3-Hydroxyanthrani1ic acid
Vanilmandelic acid
•••• continued
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Table 3.1.2.1 (continued)
MU value
18.89
18.93
19.08
19.14
19.20
19.20
19.29
19.43
19.69
19.76
19.82
19.85
19.88
20.16
20.40
20.46
20.50
20.66
20.66
20.66
20.84
21.20
21.39
21.65
21.69
21.97
22.13
22.43
22.63
24.54
Organic acid
Sebacic acid
p-Hydroxypheny1pyruvic acid*
p-Hydroxypheny11actic acid
Glucuronic acid Y-1actone*
Ga1actonic acid o-lactone
Gluconic acid o-lactone
Indo1e-3-acetic acid
4-Pyridoxic acid
U:r;-ocanic acid
Ascorbic acid-2-sulfate
Ascorbic acid
Glucuronic acid*
Undecanedioic acid
Pantothenic acid
Sa1icy1uric acid
Palmitic acid
Kynurenic acid
Ga1actonic acid
Glucaric acid
Gluconic acid
Feru1ic acid
Uric acid
Caffeic acid
Indo1e-3-pyruvic acid*
Indo1e-3-lactic acid
5-Hydroxyindo1e-3-acetic acid
Oleic acid
Stearic acid
Xanthurenic acid
Biotin
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Table 3.1.2.2 Methylene unit values for methoxime trimethylsily1
derivatives of steroids.
M. U. value
25.28
25.42
25.93
26.24
26.27
26.29
26.31
26.38
26.60
26.72
27.10
27.22
27.25
27.85
28.00
28.32
28.49
28.74
28.94
29.26
29.38
29.75
30.32
30.40
31.25
31.89
32.06
32.43
32.72
Steroid
Androsterone
Etiocholano1one
Dehydroepiandrosterone
ll-Ketoandrosterone
Estrone
5a-Androstan-3B,17B-diol
ll-Ketoetiocho1anolone
Androstenedione
B-Estradiol
Testosterone
llB-Hydroxyandrosterone
Equilenin
llB-Hydroxyetiocholanolone
Pregnanediol
5a-Cholestane
l5a-Hydroxyestradiol
Progesterone
Tetrahydrosubstance S
Estriol
Pregnanetriol
17a-Hydroxyprogesterone
Tetrahydrocortisone
Tetrahydrdcortisol
2-Hydroxyestriol
Cholesterol
Cholesterol acetate
Cortisone
Stigmasterol
Cortisol
Table 3.1.2.3 Methylene unit values for oxime trimethy1si1y1 derivatives of keto acids.
Keto acid Not oximated Methoxime Ethoxime AMU1 TMS-oxime AMU2
Pyruvic acid 10.85 10.36 11.01 0.65 11.59 0.58
ais-Oxa1acetic acid 10.88, 13.00, 13.50 10.36 11.00 0.64 11.57 0.57
a-Ketobutyric acid 11.79 10.93 11.54 0.61 11.98 0.44
a-Phenylpyruvic acid 17.01 15.63 16.14 0.51 16.34 0.20
a-Ketoglutaric acid 14.77, 16.21, 18.65 15.76 16.22 0.46 16.43 0.21
a-Ketoadipic acid 15.73, 17.10 16.58 17.04 0.46 17.27 0.23
I
p-Hydroxypheny1pyruvic acid 20.58 18.93 19.40 0.47 19.47 0.07 \Jlfo-oA
I
Glucuronic acid y-1actone 18.26, 18.44 19.14 19.72 0.58 20.29 0.57
Glucuronic acid 19.59, 20.17, 20.85 19.85 20.35 0.50 20.89 0.54
Indo1e-3-pyruvic acid 24.28 21.65 22.12 0.47 22.15 0.03
AMU1 = MU(Ethoxime) - MU(Methoxime)
AMU2 = MU(TMS-oxime) - MU(Ethoxime)
Table 3.1.2.4 Methylene unit values for oxime trimethy1si1y1 derivatives of keto steroids.
Keto steroid Not oximated Methoxime LlMUl Ethoxime 6MU2 TMS-oxime 6MU3
Mono-keto steroid:
Androsterone 24.51 25.28 0.77 25.88 0.60 26.36 0.48
Etiocho1ano1one 24.70 I 25.42 0.72 25.98 0.56 26.36 0.38
Dehydroepiandrosterone 25.25 25.93 0.68 26.55 0.62 27.11 0.56
Estrone 25.61 26.27 0.66 26.87 0.60 27.42 0.55
Testosterone 26.29 26.72 0.43 27.36 0.64 27.86 0.50
I
lJI
N
Di-keto steroid: I
Androstenedione 25.37 26.38 1.01 27.70 1.32 28.75 1.05
Progesterone 27.26 28.49 1.23 29.77 1.28 30.90 1.13
6MU1 = MU(Methoxime) - MU(Not oximated)
6MU2 = MU(Ethoxime) - MU(Methoxime)
6MU3 = MU(TMS-oxime) - MU(Ethoxime)
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without prior oximation, several keto acids produced multiple derivatives
(ois-oxalacetic acid, a-ketoglutaric acid, a-ketoadipic acid, glucuronic
acid y-lactone, glucuronic acid). Identical values were obtained for
pyrUvic acid and cis-oxalacetic acid, probably indicating decarboxylation
of the latter acid. The oximes eluted according to their order of
increasing nonpolarity: methoxime, ethoxime, TMS-oxime. The difference
in MU value (~MUl' ~MU2) between various oxime derivatives was
characteristic for each type of keto acid. Striking similarities were
seen for a-ketoglutaric acid and a-ketoadipic acid, p-hydroxypheny1pyruvic
acid and indole-3-pyruvic acid, glucuronic acid y~lactone and glucuronic
acid. Analogous results "are listed in Table 3.1.2.4 for the keto steroids.
The steroids analyzed without prior oximation produced single derivatives
eluting prior to the methoximes as would be expected from the increased
polarity of the free keto group. The difference in MU value (AMUl , ~MU2'
~MU3) between oxime derivatives was uniform for mo~?~keto steroids,
0.58 + 0.11 (mean + SD, n = 15). The corresponding difference in di-keto
steroid oximes was exactly double, 1.17 + 0.13 (mean + SD, n = 6). Thus,
the mono-keto versus di-keto shift seen with steroid oximes would be
helpful in identification of unknown keto steroids.
3.1.3 Flame ionizati~n detection
Few aspects of the flame ionization detector's operation can be
regarded as well understood (Cram et al., 1980). Response in the flame
ionization detector (FID) is believed to arise from conductivity imparted
by ions g~nerated from combustion of organic eluates in the flame
(Blades, 1973). There is a wide variation in detector geometry and
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sample handling capacity (McWilliam, 1961; Ravey, 1978). The FID is
reported to have a wide linear dynamic range (Keller, 1973), often cited
7 4
as 10 , while other detectors are usually 10 or less (Gill and Hartmann,
1967). To investigate the FID linearity, periodic response checks were
implemented. Figure 3.1.3.1 illustrates the increase in the FID linear
dynamic range following the removal of silicon dioxide deposits from the
FID collector electrodes. These deposits insulated the electrodes and
caused the FID response to falloff at high sample rates. Alexander and
Garbutt (1965) similarly found ,peak areas were 30% greater when measureme?t
was made directly after cleaning the detector. The linear range was
narrowed to a maximum upper level of 1.0 ~g of tetracosane after 72 hours
of FID operation. Thus, the practical linear dynamic range extended
from the minimum detectable level of 2.5 ng (approximately 1,000 integrator
units) to the maximum upper linear level of 1.0 ~g (approximately 400,000
integrator units) or over a range of 4 x 102•
To limit silicon dioxide deposits, the injection of freon (Walker
et al., 1977) or the use of fluorinated silylating reagents was suggested
(Stalling et al., 1968). The combustion of these reagents-was reported
to produce hydrofluoric acid which would react with silicon dioxide,
converting it to the volatile silicon tetrafluoride. Use of these
reagents did not noticeably lessen detector contamination. The rapidity
of detector electrode contamination probably varies in magnitude wi~h
the design of the detector (Margosis, 1974). While most authors do not
discuss FID contamination, others report that FID cleaning was not
required even after four years of uninterrupted use (VandenHeuvel and
Court, 1968). Routine cleaning of the FID, although time-consuming, was
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~_-""""--tl;Shours
CD(I)
C
o
a-
(I)
CD
-
c
:::s
-
-o
-(U
-OJ
CD
-C
-o
-u
CD
-CDC
-
-ID
o,..
Figure 3.1.3.1 Linear dynamic range and time-dependent
silicon dioxide suppression of the flame ionization detector
response. Times indicate the hours of continuous FID operation
since manual cleaning of the detector to remove 8i02 deposits.
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a welcome solution to the insidious problem of detector nonlinearity.
The relationship between the amount of compound present and the
FID response was determined experimentally. Aliquots of pyridine
standard solutions were methoximated, si1y1ated, andchromatographed as
shown in Figure 3.1.3.2. The relative weight response (RWR) was determined
from:
Area counts for compound
RWR = __W_e_i....g~h-:.t__o_f--:.c_om.:.....Ji,..p..:;.o..:;.u~n__d _
Area counts for tricosane
Weight .of tricosane
The weight of tricosane pre~ent was 1.00 ~g so,
'RWR = Area counts for compound
(Weight of compound)(Area counts for tricosane)·
Table 3.1.3 lists the RWR for 60 organic acids and steroids arranged in
order of increasing RWR. The small standard deviations indicate the
reproducibility of the method and the stability of derivatives. The
coefficient'of variation ranged from 11% (oxalic acid, 0.34 + 0.04,
a-hydroxyisocaproic acid, 1.43 + 0.16; a-furoic acid, 1.18 + 0.13) to
less than 1% for many compounds. The lower weight responses were characteristic
of dicarboxy1ic acids (oxalic acid, 0.34; malonic acid, 0.52;
methy1ma10nic acid, 0.79; glutaric acid, 0.86; succinic acid, 0.88),
a tricarboxylic acid (citric acid, 0.95), keto compounds (B-pheny1pyruvic
acid, 0.54; 17a-hydroxyprogesterone, 0.67; pyruvic acid, 0.69;
dehydroepiandrosterone, 0.88; cholesterol acetate, 0.88; androsterone,
0.93; estrone, 0.93). nonoximated carbonyls possessing nitrogen
(pyroglutamic acid, 0.77; orotic acid, 0.90), and methoxy compounds
(homoveratric acid, 0.65; veratric acid, 0.76; vanillic acid, 0.85;
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Figure 3.1.J.2 Gaa-liquid chro.atographic separation (flame ionization detection) of the .ethoxime tr1methylailyl derivatives of ea.e organic acids
and steroida. Analysil wal on a 6-ft 3% OV-101 coluan programmed fra. 70· to JOO·C at 4·/.in with a 4-.in initial ilotherael delay. The peaks repreaent
0.5-1.0 pg of the following co.pounds: (1) Lactic acid, (2) Oxalic acid. (3) Kethylaelonlc acid, (4) Phenylacetic acid, (5) Succinic acid, (6) Glutaric
acid. (7) Capric acid. (8) Pyroglutaaic acid. (9) Phenyllactic acid, (10) p-Hydroxyphenylacetic acid, (11) Tartaric acid. (12) Vanillic acid, (lJ) Citric
acid, (14) p-Uydroxyphenyllactlc acid. (15) Glucuronic acid, (16) S-Hydroxyindole-J-acetic acid, (17) Tricosane, (18) TetTacosane, (19) Androsterone.
(20) Dehydroeplandroaterone, (21) ~E8tradiol, (22) Pregnanediol. (23) Estriol.
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Table 3.1.3 Weight responses and stability studies of methoxime
trimethylsilyl derivatives.
The weight response is relative to the internal standard tricosane
(C23H48). :wenty identical aliquots of each pyridine standard solution
were methox~mated, silylated, and chromatographed over a 25-h period.
Methoxime trimethylsilyl derivative
Relative weight response
Mean Standard
(n = 20) deviation
Oxalic acid
Malonic acid
B-Phenylpyruvic acid
Homoveratric acid
l7a.-Hydroxyprogesterone
Pyruvic acid
Veratric acid
Pyroglutamic acid
Methylmalonic acid
Vanillic acid
Homovanillic acid
Glutaric acid
Succinic acid
Dehydroepiandrosterone
Cholesterol acetate
Orotic acid
Capric acid
Androsterone
Estrone
Citric acid
Phenylacetic acid
Homogentisic acid
Tricosane
5a.-Cholestane
Lauric acid
Suberic acid
5-Hydro~indole-3-aceticacid
0.34
0.52
0.54
0.65
0.67
0.69
0.76
0.77
0.79
0.85
0.86
0.86
0.88
0.88
0.88
0.90
0.92
0.93
0.93
0.95
0.96
0.96
1.00
1.00
1.01
1.01
1.04
0.04
0.05
0.04
0.01
0.03
0.03
0.03
0.03
0.02
0.03
0.01
0.02
0.03
0.02
0.03
0.03
0.02
0.02
0.02
0.05
0.02
0.03
0.01
0.03
0.03
0.03
••••• continued
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Table 3..1.3 (continued)
Methoxime trimethy1si1y1 derivative
Cholesterol
p-Hydroxyphenylacetic acid
p-Hydroxypheny11actic acid
Tartaric acid
Adipic acid
Lactic acid
Benzoic acid
Pheny11actic acid
Vani1mande1ic acid
Tetracosane
Pregnanediol
m-Hydroxybenzoic acid
Glucuronic acid
a-Hydroxyisobutyric acid
o-Hydroxybenzoic acid
a-Furoic acid
a-Estradiol
Estriol
p-Hydroxymandelic acid
Indole-3-acetic acid
a-Hydroxyisovaleric acid
Malic acid
P-Hydroxybenzoic acid
Mandelic acid
Caffeic acid
Gentisic acid
3,4-Dihydroxybenzoic acid
O-Hydroxypheny1acetic acid
Tropic acid
m-Hydroxyphenylacetic acid
a-Hydroxyisocaproic acid
3,4-Dihydroxyphenylacetic acid
meso-Tartaric acid
Relative weight
Mean
(n = 20)
1.05
1.06
1.08
1.10
1.10
1.11
1.11
1.11
1.11
1.11
1.11
1.12
1.13
1.15
1.18
1.18
1.18
1.18
1.20
1.20
1.21
1.22
1.26
1.27
1.28
1.30
1.32
1.33
1.34
1.43
1.43
1.46
1.55
response
Standard
deviation
0.04
0.03
0.04
0.05
0.04
0.03
0.02
0.03
0.03
0.01
0.04
0.03
0.03
0.02
0.03
0.13
0.02
0.03
0.03
0.03
0.01
0.03
0.02
0.04
0.03
0.03
0.02
0.03
0.04
0.04
0.16
0.03
0.04
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homovani11ic acid, 0.86). Po1yhydroxy compounds, which would be enlarged
by additional silyl groups, gave higher weight responses (pregnanediol, 1.11;
glucuronic acid, 1.13; e-estradiol, 1.18; estriol, 1.18; 3,4-dihydroxy-
benzoic acid, 1.32; 3,4-dihydroxyphenylacetic acid, 1.46). Other FID
response data for TMS derivatives of organic acids (Sarkar and Malhotra,
1979) and steroids (Shackleton and Honour, 1976) show similar trends.
Analysis of these variations in RWR with the chemical nature of the
compound showed a reduced response in the presence.of oxygen and nitrogen
atoms. Since authentic compounds are not always available, these trends
can be used to estimate response factors (Edwards, 1978).
3.1.4 Mass spectrometry
The repetitively acquired mass spectra were accumulated on file
and later inspected as a group, the computer-plotted chromatogram of
the total ion current (Figure 3.1.4.1). The total ion chromatogram
showed excellent agreement with the flame ionization chromatogram
(Figure 3.1.3.2) with the expected differences in response due to the
different methods of ionization. Isolated scans of special interest were
inspected individually, such as the spectrum of vanillic acid - diTMS
shown in Figure 3.1.4.2. Such histograms of normalized intensity
(% I) versus mass to charge ratio (m/e) were analyzed manually for
compound identification. Fragmentations related to the molecular ion
(parent compound minus one electron) and. fragments associated with the
trimethy1si1yl group have been tabulated by Markey et a1. (1972).
Indices arranged according to the most intense peak within windows of
specified mle (Markey et a1., 1974) simplified the identification process.
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Figure 3.1.4.1 Total ion chromatogram from the mass spectrometric detection of the methoxime trimethylsilyl derivatives of some
organic acids. GC separation was on a 6~ft 3% OV~101 column programmed from 100· to 300·C at 4°C/min with an 8~min initial iso-
thermal delay. The peaks represent 0.5-1.0 PI of the following compounds: (1) Lactic acid, (2) Oxalic acid, (3) Methylmalonic
acid, (4) Phenyladetic acid, (5) Succinic acid, (6) Glutaric acid, (7) Capric acid, (8) Pyroglutamic acid, (9) Phenyllactic acid.
(10) p-Hydroxyphenylacetic acid. (ll) Tartadc acid, (12) Vanillic: acid. (13) Citric: acid, (14) p-Hydroxyphenyllactic: acid,
(15) Glucuronic acid. (16) 5-Hydroxyindole-3-aeetic acid. (17) Tricoaane.
-62-
00300JOO mje
Figure 3.1.4.2 Electron ionization spectrum of vanillic acid-diTMS.
This histogram of normalized intensity (%1) versus mass to charge ratio -(m/e)
corresponds to scan number 210 of the total ion chromatogram shown in
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Figure 3.1.4.1. The structure of the parent compound, vanillic acid-diTMS
(MW 312), and the identities of major peaks are as follows:
mle 312, molecular ion, M (frequently seen with aromatic compounds~
mle 297, (M ~ 15) loss of a TMS methyl
mle 223, (M - 89) loss of OSi(CH3)3
m/e 73, trimethylsiliconium ion (base peak to which all other peaks were
normalized)
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The intensities of the ions associated with a peak varied between scans
obtained on the ascending or descending portion of the peak (Mamer ~ al.,
1971).
3.2 Organic acid extraction
The recoveries of fifteen organic acids from aqueous solution by
DEAE-Sephadex extraction are listed in Table 3.2. The extraction
efficiencies were calculated according to the following equation:
% Recovery = (Area counts for acid) x 100
.(Area counts ) (RWR fOr)(Weight of acid if) •
for tricosane acid 100% recovery
The relative weight response (RWR) was obtained from Table 3.1.3. The
recoveries ranged from 57.7% for pyroglutamic acid to 100% recovery for
several acids. The coefficient of variation was less than 10% for all
acids except citric acid (10.6%), oxalic acid (15.6%), and pyroglutamic
acid (18.2%). These recoveries were considerably higher and more
consistent than rE£coveries obtained by Chalmers and Watts (1972c), who
experienced 50% recove~ and often 50% coefficient of variation. The
recovery experiments, performed over a 2-year period on aqueous acid
standards stored at -30°C, showed no volatile artifacts. Figure 3.2
illustrates the gas-liquid chromatographic profile for extraction of
glutaric acid by this procedure.
Acids of special interest were subjected to the DEAE-Sephadex
procedure to check for chromatographic purity. Extraction of the aldonic
acids or their lactones (gluconic acid and gluconic acid o-lactone;
galactonic acid and galactonic acid o-lactone; ribonic acid and ribonic
acid y-lactone) gave the same equilibrium mixtures of approximately 50%
-64-
Table 3.2 Recovery of organic acids from aqueous solution by DEAE-
Sephadex extraction. The recoveries were calculated from
15 replicate determinations.
Mean Standard Coefficient
Organic acid recovery deviation of variation
% % %
Pyroglutamic acid 57.7 10.5 18.2
Lactic acid 79.3 5.5 6.9
Phenylacetic acid 84.4 3.4 4.0
Methy1malonic acid 88.7 3.9 4.4
5-Hydroxyindo1e-3-acetic acid 89.7 8.8 9.8
Glucuronic acid 90.6 3.6 4.0
Glutaric acid 92.0 7.0 7.6
Oxalic acid 93.4 14.6 15.6
Citric acid 93.7 9.9 10.6
Succinic acid 94.9 4.9 5.2
Phenyllactic acid 97.5 3.6 3.7
Vanillic acid 100.1 2.7 2.7
p-Hydroxyphenylacetic acid 102.2 2.8 2.7
Tartaric acid 102.9 5.5 5.3
p-Hydroxyphenyllactic acid 103.9 2.0 1.9
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Figure 3.2 Gaa-liquid chra.atograpbic profile of glutaric acid extracted from an aqueous solution by DEAE-Sephadex. Glutaric acid was chro.atographed
as ita diTMS derivative. Tricosane (C23"4S) vas the internal standard. Analyeis was on a 6-ft 3% oV-10l column programmed fr~ 70' to 300'C at 4'C/min
with a 4-.in initial faotherael delay.
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acid, 50% lactone. Other workeranoticed the same effect with deoxypentonic
acids (Truscott et a1., 1979a) and tetronic or deoxytetronic acids
(Thompson et al., 1975). This effect was also observed with direct
derivatization of the compounds (see Results, p.43 ) so it was unclear
when the equilibration between forms occurred. Conversely, extraction
of glucuronic acid y-1actone produced more than 90% free glucuronic acid.
Ascorbic acid extraction produced several peaks as would be expected
from its tendency to undergo oxidation accelerated by alkalies (Windholz,
1976). Conversely, ascorbic acid-2-sulfate was extracted intact.
3.3 Steroid extraction
Overall recovery of the steroid extraction procedure was determined
by carrying out the XAD-2 extraction, conjugate hydrolysis, and re-extraction
without establishing the recoveries of individual steps. Buffer pH for
deconjugation was varied between pH 4.0 and 6.0 as illustrated in
Figure 3.3.1. For routine analyses the buffer used'was pH 4.5 since
pregnanediol recovery decreased with more alkaline buffers. Leon et al.
--
(1960) identified the general-pH optimum of 4.0 - 5.0 for enzymes from
Helix pomatia. The entire procedure was tested against distilled water
as shown in Figure 3.3.2 which illustrates the purity of the steroid
extraction method. Artifacts due to Helix pomatia were not evident.
Decomposition products and artifacts are reported to be minimal for Helix
pomatia compared to other enzyme deconjugation methods (Curtius and
Muller, 1967; Roy and Slaunwhite, 1970; Manson et al., 1972). The
recoveries of steroids from an aqueous solution of steroid conjugates
are listed in Table 3.3. The recoveries ranged from 64% for pregnanediol
released from its 3a-glucuronide, to'lOO% recovery of estradiol and estriol
-67-
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Table 3.3 Recovery of steroids from an aqueous solution of steroid
conjugates by enzymatic deconjugation and subsequent XAD-2
extraction. The recoveries were calculated from triplicate
determinations.
Deconjugation was with Helix pomatia crude solution containing
S~glucuronidase and sulfatase activity (0.5 M sodium acetate~buffer,
pH 4.5; 20 h at 37oC.)
Steroid conjugate
Pregnanediol 3a-glucuronide
Estrone 3-sulfate
Dehydroepiandrosterone 3-sulfate
Estradiol 3S-glucuronide
Estriol l6a-glucuronide
Mean Standard Coefficient
recovery deviation of variation
% % %
64.2 5.1 7.9
76.3 2.8 3.7
77.4 4.5 5.8
97.0 3.1 3.2
107.8 3.5 3.2
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from their glucuronide conjugates. The coefficient of variation was
less than 10% for all steroids investigated. A major cause of loss is
almost certainly inefficient conjugate hydrolysis, especia1lyof:th"e'.
steroid sulfates. Sulfatases have a high degree of specificity toward
the steroid part of the molecule (Roy, 1970) with the result that certain
sulfates are probably not hydrolyzed (Leon et al., 1960). Other workers
have routinely experienced 90% recoveries for most steroids by XAD-2
extraction procedures (Bradlow, 1968; Shackleton et al., 1970; Matsui
et al., 1975; Leunissen and Thijssen, 1978).
3.4 Profiles of normal pregnant and nonpregnant women
3.4.1 Dietary information
Each participant completed the diet recall and diet diary forms
(Appendices D and E). The prenatal record (Appendices F and G) also
contained information concerning medications. These sources were
reviewed for unusual or extreme dietary habits. One nonpregnant woman
consumed 12 cups of coffee during the 24-hour collection period. Table
3.4.·1 summarizes the drug status of the participants. Sixty percent of
the pregnant women took a vitamin-mineral supplement while forty percent
ingested iron salts. Only one woman did not take any dietary supplements
throughout her pregnan~y. Several women ingested iron salts in addition
to vitamin-mineral supplements, leading to an intake of more than 100 mg
of elemental iron per day. Antibacterial and antifungal agents were
prescribed for three pregnant women. Occasional use of antihistaminics
and analgesics was noted, use being more frequent in nonpregnant women.
One nonpregnant woman consumed five ounces of alcohol.
Table 3.4.1 Drug status of the normal pregnant and nonpregnant women during the 24-hour collection.
The table indicates the number of subjects in each therapeutic category. The vitamin-mineral
supplements contained the following: vitamin A (1,600 - 10,000 1.U.), vitamin D (200 - 400 I.U.),
vitamin C (50 - 150 mg), iron (4 - 60 mg), calcium (0 - 134 mg), folic acid (0 - 5 mg), thiamine
(0 - 3 mg), riboflavin (0 - 5 mg), niacinamide (0 - 25 mg), pyridoxine (0 - 1 mg), cyanocobalamin
(0 - 3 mg).
Therapeutic category
(Brand name or compound·name)
Normal pregnancy (n = 25)
12~ - l5~ wk 24~ - 27~ wk
Normal
nonpregnant
(n = 15)
Vitamin-mineral supplement
(Prenavite, "Orifer-F, Paramettes)
Iron salts
(ferrous gluconate or sulfate)
Antibacterial
(Penicillin V)
Antifungal
(Monistat)
Antiseptic-antifungal
(domiphen bromide lozenges)
Antihistaminic
(Chlor-Tripolon, Dimetapp, Contac~C)
Analgesic, antipyretic
(acetaminophen, acetylsalicylic acid)
Alcohol (more th~n 2 oz.)
15
10
1
, 1
16
11
2
1
1
1
1
1
2
2
1
I
""-J
I-'
I
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3.4.2 Urinary creatinine excretion
Urinary creatinine was determined by the color reaction between
creatinine and picrate in a strong alkaline medium. The mechanism for
this' reaction probably involves the carbonyl group of the creatinine
molecule (Kammeraat, 1978). The presence of several interfering
substances possessing a carbonyl group (glucose, fructose, protein,
ket9 acids) could cause spuriously elevated values in urinary creatinine
determinations. The method of Yatzidis (1974, 1975) measures the
difference in absorbance at 500 nm of two alkaline picrate reagents, thus
subtracting the contribution of noncreatinine chromogens to give a true
creatinine concentration.
Absorbance at 500 nm was linear with creatinine concentration from
0.5 to 20 mg/dl. Results of 25 urine analyses by the Yatzidis method showed
an excellent correlation (r = 0.993) with results obtained by an automated
sequential multiple analyzer (SMA-6). The SMA-6 continuous-flow method
used dialysis to remove interfering noncreatinine chromatogens (Kammeraat,
1978).
Creatinine is a waste product of creatine metabolism. Ninety-eight
percent of the total body creatine is in skeletal muscle and 2% of
this is converted each day to creatinine (Borsook and Dubnoff, 1947).
Thus, creatinine excretion is a function of muscle mass and is roughly
proportional to body weight. Creatinine excretion (mg/24 h) did not_
change significantly with pregnancy (Table 3.4.2). A significant decrease
(P < 0.05) was observed as pregnancy progressed when the creatinine
excretion was expressed as the creatinine coefficient (mg/kg body weight/24 h).
The average weight gain between collection periods for the 25 pregnant
Table 3.4.2 Urinary creatinine excretion in normal pregnant and nonpregnant women.
Creatinine excretion/24 hour (Mean + SD)
2 /prepregnancy
mg/m BSA mg m2 BSAmg/kg BWmg
24-hour sample
collection:
time since last
------------------------menses began
(weeks)
Age Mean
range age
N' (years) (years)Group
Normal
nonpregnant 15 19-39 >:27 1 1120 + 260 18.9 + 1.9 690 ± 100 690 ± 100
Normal
pregnant 25 23-32 27 i) 12~ - 15~ 1160 + 190 19.7 + 3.0* 710 + 100 710 + 100 I
......
W
I
ii) 24~ - 27~ 1210 + 230 18.6 + 3.5* 710 + 130 750 + 130
N = Number of participants
BW = Body weight
BSA = Body surface area (Du Bois and Du Bois, 1916)
*Significant difference by paired t-test (P < 0.05)
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women was 6.7 + 1.7 kg (mean + SD). The components of this weight gain
(conceptus, maternal fat, maternal blood volume) do not contribute to
creatinine production (Clark et al., 1951). Since calculations incorporating
changes of body weight in pregnancy are illogical, Lindheimer and Katz
(1977) suggested that excretion data in pregnancy should be expressed
relative to the prepregnancy body surface area. Body surface area
increased in the 25 pregnant women from a prepregnancy value of 1.62 + 0.10 m2
(mean + SD) to values of 1.63 + 0.10 m2 and 1.71 + 0.11 m2 at the first
and second collection intervals respectively. Body surface area for the
215 nonpregnant wo~:was.~1.61 + 0.17 m. Creatinine ,excretion expressed
relative to the present or prepregnancy body surface area was not
significantly different in the three groups investigated (Table 3.4.2).
Since the subjects were reasonably homogeneous in terms of body size
(comparable prepregnancy body surface areas) and age (mean + SD : 27 + 3y
for pregnant women, 27 ± 6y for nonpregnant women), it was decided that
further evaluation of creatinine excretion would be appropriate using the
units of g/24 h.
Creatinine excretion in the nonpregnant women was 1.12 + 0.26 g/24 h
(mean + SD, n = 15) and in the pregnant women was 1.18 + 0.21 g/24 h
(mean + SD, n = 50). Investigators generally agree that creatinine
excretion does not change with pregnancy (Clark et al., 1951), although
few investigators have evaluated pregnant and nonpregnant groups sim~ltaneously.
Reported values for creatinine excretion include (g/24 h, mean + SD) :
1.03 + 0.39, n,= 14, nonpregnant (Peters et a1., 1972); 1.17 + 0.08,
n = 10, nonpregnant (Vestergaard and Leverett, 1958); 1.25 + 0.21,
n = 19, nonpregnant (Clark et a1., 1951); 1.21 + 0.18, n = 242, 12 - 40
weeks gestation (Clark et a1., 1951); 1.21 + 0.20, n = 19, 20 - 40
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weeks gestation (Chattaway ~ al., 1969).
Some individuals show great constancy of 24-hour urinary
creatinine excretion, while for others the daily excretion must be rated
as inconsistent (Vestergaard and Leverett, 1958; Scott and Hurley, 1968;
Edwards et al •. , 1969). Generally, creatinine excretion in an individual
rarely varies more than 10 to 15% and when it does, a collection error
is usually identified (Lindheimer and Katz, 1977). Of the 25 pregnant
women investigated, there were four whose daily creatinine excretion
was greater at the second collection by more than 15% (by 21%, 26%,
28%, and 31%), as shown in Figure 3.4.2.1. Daily creatinine output does
not depend on urinary volume (Cramer et al., 1967). The 65 samples had
volumes of between 0.380 and 2.435 1 (1.32 + 0.43 1, mean ± SD). A
highly significant inverse correlation (r = -0.790, p < 0.001) was
observed between 24-hour urine volume and creatinine concentration
(Figure 3.4.2.2). Metcalf (1977) observed an identical correlation
(r = -0'.180) for 81 samples of nonpregnancy urine. An incomplete 24-h
sample would be indicated by a value in the 1qwer left segment of
Figure 3.4.2.2 (low urine volume and low creatinine concentration).
The two points farthest below the correlation line (0.585 1, 1.03 gIl
and 0.820 1, 0.74 gIl) represent creatinine excretion in the same woman
at 13~ weeks and 27~ weeks of pregnancy. This would tend to indicate that
the woman is a low excretor of creatinine (consistently 0.60 g/24 h~
also see Figure 3.4.2.1), but one cannot dismiss the possibility of uniform
losses of a portion of the total 24-hour sample. Incomplete collection
would be implicated if the 24-hour excretion of other urinary metabolites
was also below the average value expected. Some pregnancies may be
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associated with diminished creatinine excretion since creatine excretion
may be increased in pregnancy (Clark et al., 1951). Renal changes
associated with hypertension during pregnancy may also decrease the 24-h
urinary creatinine excretion (Legge, 1980). Chattaway et ale (1969)
--
investigated 10 pregnant women with pre-eclamptic toxemia at 32 - 40
weeks gestation and reported creatinine excretion of 0.79 + 0.49 g/24 h
(mean + SD). Failure to empty the bladder completely due to urinary
tract dilatation and increased urinary tract dead space may cause errors
in the collection of timed urine samples in pregnancy (Lindheimer and Katz,
1977).
Samples deviating above the correlation line in Figure 3.4.2.2
(for example, 0.89 1 with 2.14 g creatinine/I) may represent more than
a 24-h collection. A high-creatine meat diet (Barrett and Addis, 1947)
and intense physical exercise (Doolan ~ al., 1962) may each increase
urinary creatinine excretion by 10%. Some authors report an increase in
creatinine excretion during a 24-h fast (Tocci et al., 1972) while
others have reported a decrease (Peters et a1., 1972). Large elevations
of urinary creatinine have been observed in schizophrenic patients during
a transient psychotic episode (Pscheidt et a1., 1966), indicating that
emotional state may influence creatinine metabolism. Increased urinary
17-ketosteroid excretion (principally dehydroepiandrosterone,
etiocholano1one, and androsterone) has been associated with elevated
urinary creatinine excretion, suggesting hormonal control of muscle mass
and thus creatinine output (Clark et al., 1951).
Despite the many factors influencing creatinine metabolism, the
results above indicate that creatinine excretion did not change with
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pregnancy. The daily excretion of creatinine was fairly constant as judged
by intra-individual and inter-individual comparisons. Considering this
constancy and the fact that instructions for specimen collection were
stressed by written and verbal directions, we can be reasonably confident
that the samples represent complete 24-h collections. -For future
reference, Figures 3.4.2.1 and 3.4.2.2 could be used to estimate the
completeness of 24-h collections. Samples with a low creatinine content
and below average content of other urinary metabolites probably
represent incomplete collections. Excretion values in those cases
could be corrected to give an equivalent of 1.0 g of cr~atinine per
24 hours. Knuppel et al.(1979) examined 489 urine collections in
pregnancy and suggested that 24-h urine volumes less than 500 m1 be
corrected to give 1.08 g of creatinine per 24 hours.
3.4.3 Urinary organic acid excretion
Each urinary specimen was assayed in duplicate by the organic
acid extraction method. An aliquot of aqueous glutaric acid was
added toone sample, while aqueous a-phenylpyruvic acid was added-
to the other sample. These acids were chosen as recovery standards
because they eluted in uncrowded portions of the urinary acid chromatogram.
Any urinary peaks coeluting with these recovery standards were expresse~
relative to another urinary peak and subtracted to give the corrected
area for each recovery standard. The recovery of glutaric acid (a
dicarboxylic acid) was 95.1 + 8.3% (mean + SD, n = 76). The recovery
of a-phenylpyruvic acid (a keto, monocarboxylic acid) was 95.6 ± 7.6%
(mean + SD, n = 76).
The urinary acid chromatograms contained several distinct peaks,
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as well as many peaks which were poorly resolved from the major constituents.
The complex chromatograms were interpreted by a series of calculations.
The preliminary visual comparison of chromatograms was followed by the
tabulation of peak areas into 50 recognizable peaks. Peaks which were
not consistently resolved were combined into one peak report, which of
course represented more than one recognizable component. All component
areas were corrected to give 100% recovery by the glutaric acid or
B-phenylpyruvic acid recovery data. The component areas were then
expressed relative to the internal standard (n-tricosane) and corrected
for total 24-h urine volume. Final results were expressed in terms of
relative amount of component/24 h. The relative amount/24 h was
transformed to mg/24 h by a conversion factor which could be applied
when peak identity was confirmed. The conversion factor considered the
extraction efficiency as well as the FID response factor unique for each
compound. Figure 3.4.3.1 summarizes the series of calculations involved
in the quantitation of identified metabolites. Table 3.4.3.1 lists
the conversion factors for several organic acids. Not surprisingly,
acids of similar structure had similar conversion factors, reflecting
comparable extraction efficiencies and chromatographic characteristics.
The 2-~1 injection produced a chromatogram of the constituents
in an aliquot of urine containing 4 pg of creatinine (the equivalent of
1 mg of creatinine was extracted, while only 1/250 of the derivatized
extract was injected into the gas chromatograph). A chromatogram of
the acidic metabolites extracted from the urine of a normal pregnant
woman at the 27th week of gestation is shown in Figure 3.4.3.2. The
corresponding total ion chromatogram from mass spectrometric analysis
The quantitation of identified metabolites was calculated according to the following formula:
mg/24 h = Relative amount/24 h x Conversion factor
Relative amount/24 h = Area counts for compound x
(
.. Area counts ) (ReCOVery of glutaric )
for tricosane or a-phenylpyruvic acid
24-h urine
volume (ml)
Urine volume
extracted (ml)
1 mgx _-----:_w--_
1000 llg
Derivatization volume (~l)
x Injection volume (~l)
1
(
Relative Weight)
response
of compound
1
factor = (. ExtractiOn) x
efficiency
of compound
Conversion
Extraction efficiency = see Table 3.2, page 64
of compound
Relative weight = RWR = see Table 3.1.3, page 58
response of compound
I
00
,.....
I
Derivatization volume = 500 ~1
Injection volume = 2 ~l
Where the ex~raction efficiency or relative weight response of the compound was not known, an estimate
was made by consideration of structural similarities with other compounds.
Figure 3.4.3.1 Quantitation of identified metabolites.
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Table .4.3.1 Conversion factors for organic acids. (See Figure 3.4.3.1
for an explanation of the conversion factor.)
Organi acid
Ionic
Glutaric
Phenylacetic
Succinic
Vanillic
Lactic
Citric
5-Hydroxyindole-3-acetic
Glucuronic
Phenyllactic
p-Hydroxyphenylacetic
p-Hydroxyphenyllactic
Tartaric
Type of acid
dicarboxylic
amido, monocarboxylic
dicarboxylic
dicarboxylic
phenyl, monocarboxylic
dicarboxylic
methoxy, hydroxy,
phenyl, monocarboxylic
hydroxy, monocarboxylic
hydroxy, tricarboxylic
hydroxy, indole,
monocarboxylic
aldehydo, hydroxy,
monocarboxylic
hydroxy, phenyl,
monocarboxylic
hydroxy, phenyl,
monocarboxylic
hydroxy, phenyl,
monocarboxylic
hydroxy, dicarboxylic
Conversion
factor
0.787
0.563
0.357
0.316
0.309
0.299
0.294
0.284
0.281
0.268
0.244
0.231
0.231
0.223
0.221
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is shown in Figure 3.4.3.3. Ten urinary acidic metabolites were identified
by their mass spectra which matched previously published spectra
(Markey et al., 1972; Markey et al., 1974; Thompson et al., 1975).
While approximately 50 spectra were deemed to be of special interest,
only the prominent peaks in the chromatogram were unequivocally identified.
These prominent peaks were more easily identified due to their single
component nature. In contrast, multicomponent peaks were difficult to
interpret due to superimposed spectra (Mamer et al., 1971). The 4-carbon
hydroxy-acid isomers erythronic acid and threonic acid gave identical
spectra (Thompson et al., 1975). Ion intensities also varied according
to the portion of the peak scanned. Background spectra due to the
stationary phase and derivatizing reagents also probably complicated
the mass spectral data (Brooks and Middleditch, 1971). The linear
dynamic range of the mass spectrometer was narrower than desired. As
a result, there was a tendency for major urinary c()mponents to overload
the mass spectrometry system, while minor components were not identified.
The introductory analyses performed assured us thatLthe system was
working correctly. Further analyses to identify minor urinary acidic
metabolites should be performed on concentrated samples after removal
of excess reagents.
Tables 3.4.3.2, 3.4.3.3, and 3.4.3.4 contain a complete list of
the urinary acidic metabolites as well as 24-h excretion data for the
pregnant and nonpregnant women. Columns in the tables indicate the
possible identity of a peak (determined by coinjection of authentic
acids), the confirmed identity of a peak (determined by mass spectrometry),
and the identity of a peak according to other workers (Lawson et ale 1976;
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Table 3.4.3.2 Acidic metabolite excretion in normal pregnant and nonpregnant women. Group 1: Metabolites detected 1n all samples and fully
quantitated.
The possible identities of peaks were determined by coinjection of derivatized acid standards. Unequivocal confirmation of peak identity
was achieved only by gas chromatography-masliJ spectrometry (GC-MS).
The 24-h excretion data were calculated relative to the internal standard tricoaane. An unpaired t-test was used to coapare excretion
in nonpregnant women to excretion in pregnant women at each stage of pregnancy. The significance l~vels are indicated in the columna of pregnancy
data. A paired t-test compared the excretion data of pregnancy.
*p < 0.05
..p < 0.01
*"P < 0.001
§ Compounds identified by other workers (Lawson et al., 1976; Petersson,1977; Cohn !!!!.• 1978).
I
(X)
Confirmed 0'I
Peak MU Possible peak identity identity Compounds identified Paired
number value authentiC acids coin ected b GC-HS b other workers§ wk t-teat
1 10.63 LacUcac1d Lactic acid Lactic add 71! 76 227 ! 271* 416 ± 324*" *
2 10.74 Glycolic acid Glycolic acid Glycolic acid 154 ± 94 326 ± 99*" 380 ± 122*** •
3 11.26 Oxalic acid Oxalic acid 149 ! 75 151 ± 89 164 ± 79
8 12.15 Hethylmalonic acid Hethylmalonlc acid 73 ± 26 103 ± 40* 100 ± 32**B-Hydroxyisovaleric
acid
10 12.41 Levul1nic acid 70 ± 35 59 ± 31 78 ± 42
12 13.15 Succinic acid Succinic acid 208 ± 63 257 ± 71* 259 ± 61*Pyrotartaric acid
13 13.51 Glyceric acid
Pyrrole-2-earboxylic acid Glyceric acid 89 ± 52 Hl± 70 124 ± 53*
FUlIlIlric acid
14 13.67 4-Deoxyerythronic acid
and Plpecol1c acid 223 ± 96 328 ± 89** 490 ± 122*** ***
lJ.14 4-Deoxythreon1.c add
17 14.12 39 ± 30 1l± 44* 61 ± 36
19 14.56 Capric add 2-Deoxytetronic acid 74 ± 19 112± 48** 124 ± 49***
•••• continued
Table 3.4.3.2 (continued)
Confirmed Relative amount/24 h (mean ± SD)
Peak HU Possible peak identity identity Compounds identified t-lonpregnant Pregnant (n • 25) Paired
number value (authentic acids coinjected) by GC-HS by other workersS (n • 15) 12"-151 wk 241j-21!j wk t-test
21 15.02 Salicylic acid Adipic acid 101 ± 84 105 ± 52 123 :!:. 56
to Adipic acid Pyroglutamic acid
15.11 Acetopyruvic ~cid
Malic acid
Pyroglutamic acid
22 15.34 3-Methyladipic acid 5-Hydroxymethyl- 54 ± 31 80 ± 51 98 :!:. 55**to 2-furoic acid
15.49
25 15.82 a-Ketoglutaric acid Erythronic !:!!. Erythronic acid 313 ± 84 427 :!:. 101 496 ± 115*** **fl-Phenyllactic acid threonic acid a-Ketoglutaric acid
26 15.99 m-Hydroxypheny1acetic acid Erythronlc !:!!. Threonic acid 218 ± 174 301 :!:. 135 310 :!:. 154Pimelic acid Threonic acid m-Hydroxypheny1acetic I
acid 00
"'-J
28 16.27 B-Hydroxy-B-methylg1utaric acid B-Hydroxy-B-methyl- I
glutaric acid 114:!:. 55 136 :!:. 80 151 :!:. 13p-Hydroxyphenylacetic acid p-Hydroxypheny1acetic
acid
32 16.92 3-lndoxylaulfuric acid Suberic acid
to Suberic acid Deoxypentonic acids 149 ± 38 205 :!:. 96* 218 :!:. 85**
17.03 Ribonic acid y-lactone
35 17.62 Homovani11ic acid HolDOvanillic acid
a-Glycerophosphoric acid cis-Aconitic acid 268 ± 12 310 ± 84 386 ± 119*
ois-Aconitic acid
39 18.91 Vanilmandelic acid Vanilmandelic acid
Sebacic acid m-Hydroxyphenyl- lI2± 19 107 :!:. 36 108 ± 38
p-Hydroxyphenylpyruvic acid hydracrylic acid
40 19.11 p-Hydroxyphenyllactic acid Gluconic acid
to Glucuronic acid y-lactone 6-bctone
19.32 Galactonic acid 4-lactone Deoxyhexonlc acida 551 :!:. 281 557 ± 171 592 :!:. 221
Gluconic acid a-lactone
tndole-3-acetic acid
43 19.89 Ascorbic acid-2-au1fate Glucuronic acid Glucuronic acid 321 ± 121 389 :!:. 145 411 :!:. 141
Ascorbic acid
Glucuronic acid
Undecanedioic acid ••••• contlnued
Table 3.4.3.2 (continued)
Peak
number
47
50
MU Possible peak identity
value (authentic acids coinjected)
20.59 Galactonic acid
Glucaric acid
Gluconic acid
22.01 5-Hydroxyindole-3-acetic acid
Confirmed
identity
by GC-HS
Compounds identified
by other workers§
Glucaric acid
Gluconic acid
S-Hydroxyindole-J-
acetic acid
Relative all\Ountl 24 h (mean ± SD)
Nonpregnant Pregnant (n • 25) Paired
(n • 15) 12lt15; wk 24~-27; wk t-test
126 ± 74 135 ± 67 US± 74
57 ± 58 72 ± 76 68 ± 45
I
00
00
I
Table 3.4.3.3 Acidic metabolite excretion in normal pregnant and nonpregnant women. Group 2: Metabolites detected in all samples but not
fully quantitated. (See Table 3.4.3.2 for details.)
Category
A. Off-scale peaks
B. Partially obscured
peaks
Peak MU Possible peak identity
number value (authentic adds coin1ected)
5 11.48 Sulfate
11 12.90 Phosphate
37 18.00 Hippuric acid
38 18.50 Citric acid
49 21.30 Uric acid
caffeic acid
4 11.38 a-Hydroxybutyric acid
6 11.67 a~Hydroxybutyric acid
1 12.02 Malonic acid
27 16.18 p-Hydroxybenzoic acid
36 17.86 p-Uydroxymandelic acid
a-Glycerophosphoric acid
41 19.45 4-Pyridoxic acid
B-Hydroxybutyric acid
B-Hydroxyisobutyrlc acid
p-Hydroxymande1ic acid
Table 3.4.3.4 Acidic metabolite excretion in normal pregnant and nonpregnant women. Group 3: Metabolites not detected in all samples.
(See table 3.4.3.2 for details.)
Confirmed
Peak MU Possible peak identity identity
number value (authentic acids coinjected) by GC-MS
9 12.27 Benzoic acid
15 13.93
16 14.00 Glutaric acid
18 14.33 a-Keto-y-methlo1butyric acid
3.3-Dimethy1g1utaric acid
20 14.83 Citramaltc acid
to
14.90
23 15.58 a-Hydroxyphenylacetic acid
m-Hydroxybenzoic acid
24 15.63 8-Phenylpyruvic acid
29 16.43 Imldazoleacetic acid
30 16.60 a-Ketoadipic acid
31 16.10 'rartaric acid
Compounds identified
by other workers§
Benzoic acid
Glutaric acid
3-Deoxytetron!c acid
3-Hethylglutaconic acid
Tartaric acid
Number of subjects excreUng detectable amounts
(Range of excretion in relative amount/24 h)
Nonpregnant Pregnant (n • 25)
(n • 15) 12~-15; wk 24;-27; wk
0 9 9
(21 - 670) (24 - 331)
1 8 10
(16) (trace - 97) ( 6 - 214)
12 20 15
( 6 - 74) (trace - 174) (trace - 197)
11 23 25
(trace - 93) (20 - 116) (trace - 110)
15 23 23
(13 - 65) (15 - 94) (21 - 94)
1 5 4
(19) (12
- 63') (24 - 105)
0 1 0
(43)
15 23 21
(trace -87) (trace - 171) (trace - 185)
5 17 14
(trace
- 91) (trace - 70) (trace - 145)
10 19 20
(31 - 504) (40 - 1210) ( 1 - 598)
••••• continued
I
\0
o
I
Table 3.4.3.4 (continued)
Confirmed
Peak HU Possible peak identity identity
number value (authentic acidscoin1ected) by GC-MS
33 17.16 QuinoUnic acid
34 11.30
42 19.53
44 20.03
45 20.30
46 20.43 Salicyluric acid
48 20.82 Ferul1c acid
Number of subjects excreting detectable amounts
(Range of excretion in relative amount/24 h)
Compounds identified Nonpregnant Pregnant (n • 25)
by other workers§ (n • 15) 12~-15~ wk 24~-21~ wk
2 3 1
(33 - 64) (trace - 11) (35)
I
4 3 3 \0
( 4 - 274) (16 - 89) (10 - 49) ....I
9 11 18
(42 - 71) (30 - 143) (23 - 211)
0 0 1
(386)
3 0 3
(44 - 115) (60 - 99)
Sal1cyluric acid 3 2 2
(420 - 3114) (12 - 21) (14 - 127)
4 18 10
(120 - 136) (trace - 183) (trace - 110)
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Petersson, 1977; Cohn et al., 1978). The metabolites were grouped
according to prevalence of excretion of detectable amounts, and listed
in order of chromatographic elution. The minimum detectable amount
was-1-2 mg excreted/24 h. In crowded regions of the chromatogram, 5 mg
excreted/24 h was needed to identify a metabolite as a distinct peak.
The three acidic metabolite groupings consisted of: group 1, metabolites
detected in all samples and fully quantitated (Table 3.4.3.2); group 2,
metabolites detected in all samples but not fully quantitated (Table
3.4.3.3); and group 3, metabolites not detected in all samples (Table 3.4.3.4).
Table 3.4.3.2 shows the means and standard deviations for acidic
metabolites detected in all samples analyzed. The wide range of standard
deviations (some + 100% of the means) indicated the variability in
organic acid excretion among normal subjects. An unpaired Student's t
test was used to compare excretion in nonpregnant women to excretion in
pregnant women at each stage of pregnancy. A paired Student's t test
compared the excretion data of pregnancy. Of the 22 peaks in group 1,
10 peaks showed no significant difference between the nonpregnant and
pregnant groups. No decreases were observed in 24-h excretion for the
pregnant women compared to the nonpregnant women. Conversely, 12
acidic metabolites were excreted in greater amounts in pregnancy. Three
metabolites, peak 13 (probably glyceric acid), peak 22 (probably
5-hydroxymethyl-2-furoic acid), and peak 35 (probably homovanillic acid
and cis-aconitic acid) were significantly increased at the second
trimester collection only. Five metabolites, peak 8 (probably
methylmalonic acid and a-hydroxyisovaleric acid), peak 12 (probably
succinic acid and pyrotartaric acid), peak 17 (unknown), peak 19
-93-
(probably 2-deoxytetronic acid), and peak 32 (probably suberic acid and
deoxypentonic acids) were significantly increased at the first trimester
collection with only slight changes as pregnancy progressed. Four
metabolites, peak 1 (lactic acid), peak 2 (glycolic acid), peak 14 (probably
the 4-deoxytetronic acids), and peak 25 (erythronic acid) were excreted
in greatly increasing amounts as pregnancy progressed. These last
four metabolites were major urinary peaks and thus unequivocally identified
(except the 4-deoxytetronic acids). Since all were aldonic acids
(hydroxy, monocarboxylic acids) the relative amount/24 h excretion
data were converted to Vmol/24 h using the lactic acid conversion factor
of Table 3.4.3.1. The resultant excretion data are listed in Table
3.4.3.5 which also gives the range of values for each group of women.
Since excretion of these four acidic metabolites showed such a dramatic
increase in pregnancy, pairs of metabolites were further investigated
to identify simultaneous increases in excretion. Table 3.4.3.6 gives
the correlation coefficients for the paired urinary acidic metabolites.
Lactic acid excretion correlated poorly with the excretion of the other
acids. The excretion patterns for the remaining acidic metabolites
(glycolic acid, erythronic acid, and the 4-deoxytetronic acids) correlated
very well, possibly indicating a common origin. Figure 3.4~3.4 is a
graphic illustration of the correlation between glycolic acid excretion
and 4-deoxytetronic acid excretion. The excretion values for urinary
acidic metabolites in four 24-h urine samples from one nonpregnant woman
were remarkably consistent (see Figure 3.4.3.4). The excretion data for
that individual remained constant over the year in which the samples
were collected, regardless of dietary or seasonal conditions. Such
Table 3.4.3.5 Urinary excretion of some organic acids in normal pregnant and nonpregnant women.
24-h excretion, ~mo1/24 h + SD
(range) -
Organic acid
Nonpregnant
(n = 15)
Pregnant (n = 25)
12~ - 15~ wk 24~ - 27~ wk
Paired
t-test
Lactic acid
Glycolic acid
4-Deoxytetronic acids
Erythronic acid
240 + 240 710 + 870* 1310 + 1020***
(50 - 840) (90 -4060) (210 - 4200)
570 + 350 1220 + 370*** 1420 + 460***
(160 -1490) (640 -2000) (790 - 2530)
530 + 230 780 + 210** 1160 + 290***
(210 - 990) (460 -1240) (740 ..... 1700)
780 + 180 890 + 220 1040 + 240***
(420 -1090) (520 -1290) (530 - 1410)
*
*
***
**
I
\0
.f::'
I
*p < 0.05 (Statistical significance was calculated as in Table 3.4.3.2)
**p < 0.01
***p < 0.001
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Table 3.4.3.6 Correlation between paired urinary acidic metabolites
in pregnant and nonpregnant women.
Lactic acid
**0.386
**0.360
Glycolic acid
***0.667 4-Deoxytetronic acids
***0.406 ***0.584 ***0.621 Erythronic acid
**Correlation significant at P < 0.01
***Correlation significant at P < 0.001
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~igure 3.4.3.4 Correlation between glycolic acid excretion and 4-deoxy-
tetronic acid excretion for pregnant and nonpregnant women. (. nonpregnant
women, n • 15; .pregnant women, 12~15~ weeks gestation. n· 25; ... pregnant
women, 24~27~ weeks gestation, n • 25) The four points circled in the -
lower left segment of the graph represent excretion values for one nonpregnant
woman who collected a 24-h urine sample at four separate intervals over a
I-year period.
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uniform intra-individual data would support the concept of biochemical
individuality (Williams, 1956).
Table 3.4.3.3 lists the metabolites detected in all samples but
not· quantitated. Metabolites present in large amounts produced off-scale
peaks, overloading the flame ionization detection system and resulting
in nonlinear detection. These off-scale peaks (sulfate, phosphate,
hippuric acid, citric acid, uric acid) usually had a wide methylene unit
range. Such peaks partially obscured several smaller peaks which were
seen as inconsistently resolved shoulders on the large peaks. The large
sulfate and phosphate peaks especially dominated the early portion of
the chromatogram. It would have been possible to quantitate the large
peaks by injecting less of the derivatized sample into the gas chromatograph.
Uric acid showed a tendency to precipitate out of solution and disappear
from the chromatogram.
While metabolites detected in all samples are probably endogenous,
metabolites detected in only a few samples are likely of exogenous
origin. Table 3.4.3.4 lists 17 peaks whose occurrence was irregular,
probably influenced by diet and drugs (Chalmers et al., 1976a) or
other factors such as intestinal microorganisms (Scheline, 1968).
Figure 3.4.3.5 shows the gas-liquid chromatogram of a normal pregnancy
at 27 weeks of gestation which has a large amount of peak 31 (probably
tartaric acid) and peak 50 (probably 5-hydroxyindole-3-acetic acid)._
Compounds such as 5-hydroxymethyl-2-furoic acid and tartaric acid are
mostly of dietary origin (Lawson !! al., 1976; Pettersen and Jellum,
1972). The ingestion of foods containing serotonin (for example, bananas).
can increase the 5-hydroxyindole-3-acetic acid excretion markedly
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(Crout and Sjoerdsma, 1959). Pharmaceutical preparations may also
produce unusual urinary acidic metabolites (Chalmers et a1., 1976a).
A peak corresponding to sa1icy1uric acid (peak 46) was observed in women
who 'ingested acetylsalicylic acid. Salicyluric acid formation (s~licy1ic
acid conjugation with glycine) is the main route of salicylic acid
elimination (Arosel and Levy, 1969), although alterations in intestinal
flora may cause patients with gastrointestinal dysfunction to excrete
salicyluric acid even though they do not receive salicylates (Finnie et al.,
1976). Peak 44 was observed in only one woman who also ingested an
antihistaminic (Dimetapp: contained brompheniramine, phenylephrine, and
phenylpropanolamine). Peak 34 was greatly elevated in one nonpregnant
woman who ingested acetaminophen. No additional urinary peaks were
observed for the nonpregnant woman who consumed 5 ounces of alcohol
although ethyl a-D-glucosiduronic acid has previously been identified
as a metabolite of ethanol in man when alcoholic volumes were consumed
(Jaakonmaki et al., 1967a). None of the nonpregnant women had detectable
amounts of benzoic acid in their urine, while several pregnant women
had considerable quantities present: Benzoic acid may be produced as
the result of hippuric acid hydrolysis by hippuricase-forming bacteria
in the urine (Hansen ~ al., 1972). At least one pregnant woman had
greatly increased amounts of benzoic acid in the urine due to the use
of an antifungal agent (MOnistat) which contained benzoic acid. Such
overt alterations to the urinary acid chromatogram stressed the importance
of considering drug metabolites or drug-induced metabolites when an
unusual peak was encountered.
Further characterization of the urinary acid chromatogram was
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carried out by a variety of procedures. Different oximating agents
were employed to aid in the identification of keto acids. Glucuronic
acid was the only keto acid clearly observed, while occasionally the
peaks corresponding to a-ketoglutaric acid were seen. Careful
consideration was given to an extensive list of 300 substances (antioxidants,
putrefactive compounds, food additives, plasticizers, etc.) commonly
encountered in biological fluids (Ramsey et a1., 1980), although no
such compounds were identified. The effect of specimen storage on the
urinary acid profile was also investigated. Figures 3.4.3.6 and 3.4.3.7
show chromatograms of a urinary sample stored at -30~C for 5 months and
13 months, respectively. The·chromatograms were identical, any minor
differences being solely due to GC column performance. Indeed, the
resolution of peak 1 (lactic acid) from peak 2 (glycolic acid) served
as a good indicator of GC column performance. Retention times for the
two peaks differed by O~40 min with a newly packed GC column while a
difference of less than 0.35 min indicated that the column needed to be
repacked. Several urinary acid peaks were not always resolved. Peak 14
eluted as a single peak (MU 13.68) and as a doublet (MU 1J.67 and
MU 13.74). In addition, peaks 22 and 32 each encompassed at least two
different compounds but inconsistent resolution necessitated the
tabulation of peak areas as single peak reports.
The precision of the method was assessed using duplicate analyses
as shown in Table 3.4.3.7. The coefficient of variation for the four
peaks investigated (peak 1, lactic acid; peak 2, glycolic acid; peak 14,
probably the 4-deoxytetronic acids; peak 25, erythronic acid) was
usually less than 10%. The coefficient of variation varied only slightly
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Table 3.4.3.7 Assessment of precision of the method using duplicate analyses.
The coefficient of variation (CV) of the results of duplicate determinations from their means
, was determined by the following (Snedecor, 1952; Abraham et al., 1971):
cv =~Ed2 where d = [highest value of each duplicate ~ lJ x 100
2n lowest value of each duplicate
and n = number of duplicate determinations.
The four prominent urinary acidic metabo1ies were used for the precision calculations. Ten duplicate
determinations were performed by the same assay method on seven different days.
Coefficient of variation (CV) of the results of duplicate
determinations from their mean (%) Overall CV
Peak Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 (%)
no. Organic acid n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 10 n = 70 Jt-'
0
6.5 6.4 11.8 w1 Lactic 6.3 13.8 7.9 3.8 8.7 J
2 Glycolic 12.3 4.6 8.3 5.9 5.1 3.6 11.2 8.1
14 4-Deoxytetronic 7.9 9.2 7.3 14.9 6.2 11.4 13.2 10.4
25 Erythronic 9.8 5.3 3.7 14.6 9.7 7.7 7.9 9.1
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Table 3.4.3.8 Assessment of precision of the method according to the
analytical range of determinations.
The coefficient of variation was determined as in Table 3.4.3.7.
Data for the four prominent urinary acidic metabolites (lactic acid,
glycolic acid, 4-deoxytetronic acids, erythronic acid) were grouped
according to analytical range.
Analytical range Number of Coefficient of
of determinations duplicate variation
(Relative amount/24 h) determinations (%)
< 49 10 11.8
50- 99 19 9.4
100-149 24 7.8
150-199 22 13.1
200-299 46 9.2
300-399 62 8.0
400-499 48 8.3
500-599 30 10.6
600-699 10 4.7
> 700 9 5.1
Al1.va1ues 280 9.1
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according to the analytical range of determinations (Table 3.4.3.8).
Thus, the organic acid extraction method had good analytical precision
for the urinary acids investigated.
3.4.4 Urinary steroid excretion
The urinary steroid chromatograms contained several poorly
resolved peaks. A chromatogram of the steroid metabolites extracted
from the urine of a normal pregnant woman at the 27th week of gestation
is shown in Figure 3.4.4.1. The corresponding total ion chromatogram
from mass spectrometric analysis is shown in Figure 3.4.4.2. Pregnanediol
(peak 8) was the only steroid metabolite identified from its mass spectrum.
Table 3.4.4 contains a list of the possible peak identities. The steroid
chromatogram was similar to published steroid profiles of pregnancy urine
with pregnanediol and estriol as the predominant peaks (Horning et al.,
1971; Fotsis ~ al., 1980). Capillary columns would, however, produce a
profile where individual metabolites could be quantitated (Pfaffenberger
and Horning, 1975). Indeed, the doublet of peaks corresponding to
androsterone and etiocholanolone (peaks 1 and 2) provide an indication of
the lack of resolution with the 6-ft packed columns.
Analysis of urine from nonpregnant women revealed small peaks
corresponding to androsterone,etiocholanolone, 116-hydroxyandrosterone,
116-hydroxyetiocholanolone, and pregnanediol as would be expected for
the follicular phase of the menstrual cycle (Ros and Sommerville, 1971;
Viinikka and Janne, 1973; Fantl and Gray, 1977).
An aliquot of urine equivalent to 40 pg of creatinine was needed
to produce a good urinary steroid profile. Since the Amberlite XAD-2
PREGNANT
(27 wk)
Q)
(/)
c
0
a. I
(/) ....
Q) 00\
... 8 I
... 100
.....
(J
Q)
.....
Q) 12
0
6050402010o 30
Time (min)
Figure 3.4.4.1 Gae-liquid chroaatoara- of steroid aetabolites extracted fra. the urine of a nor.al pregnant wa.an at the 27th week of gestation.
The aethodlll8 tr1l1ethylsllyl derivatives vere analyzed on a 6-ft 3% OV-IOI collaD progra.-ed frOlll 70· to 300·C at 4·C/aln vith a 4-.in initial
isother.al delay. Injection volU1118 vas 2 ~l. ~lification vas 10 x 16 (via electronic integration). The chromatograa represents an aliquot of
urine equivalent to 40 ~g of creatinine. Peak numbers correspond to possible peak identifications given in Table 3.4.4.
100
..-..
~80
'-"
>-
+J
.-(J) 60C I
Q) ....0
+J
......C I
.-
+J
C 40 8Q)
a..
a..
:s
(,)
c: 20
0
o 100 200 400
Scan number
Figure 3.4.4.2 Total ion chromatogr.. from the ..aa apectroaettic detection of the aethoxime triaethylailyl derivatives of the
steroids extracted from the urine of a normal pregnant woman at the 27th week of gestation. GC separation was on a 6-ft 3% OV-I0l
coluan programmed from 100· to 300·0 at 4·C/aln with an 8-ain lnitial iaothermal delay. Peak numbera correapond with the gaa-
liquid chromatogram 6f the same saaple shown in Figure 3.4.4.1. Peak 8 wss identified.by the maaa spectrum 4a pregnanediol-diTHS.
-108-
Table 3.4.4 Steroid metabolite exc"retion in a normal pregnant
woman at the 27th week of gestation.
The possible identities of peaks were determined by coinjection
of derivatized steroid standards.
*Peak 8 was identified by the mass spectrum as pregnanediol-diTMS.
Peak
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
MU
value
25.24
25.37
25.90
26.34
26.57
27.14
27.26
27.77
28.61 .
28.88
29.33
29.50
30.20
30.50
Possible peak identity
(authentic steroids coinjected)
Androsterone
Etiocholanolone
Dehydroepiandrosterone
ll-Ketoandrosterone, Estrone, 5a-Androstan-3B,17B~
diol, ll-Ketoetiocholanolone, Androstenedione
B-Estradiol
IIB-Hydroxyandrosterone
IIB-Hydroxyetiocholanolone
Pregnanediol*
Tetrahydrosubstance S
Estriol
Pregnanetriol
Tetrahydrocortisone
Tetrahydrocortisol
2-Hydroxyestriol
15 30.75
16 31.25 Cholesterol
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resin adsorbs steroid conjugates quantitatively from as much as 40 times
its volume of urine (Osawa and Slaunwhite, 1970), the aliquot of urine
extracted can be adjusted to produce suitable chromatograms. The
ine·fficiency of enzyme deconjugation would probably be the greatest
drawback of the present method. Certain steroid sulfates are not
hydrolyzed by enzymes from Helix pomatia (Leon et a1., 1960). While
urinary steroids are predominantly excreted as glucuronide conjugates,
approximately 10% of the total steroids are mono- or disulfate conjugates
(Eriksson and Gustafsson, 1970, 1972).
3.5 Profiles of some risk pregnancies
Acidic metabolite excretion was investigated in several cases of
high-risk pregnancy. Some of these pregnancies resulted in the death of
the fetus or neonate. Table 3.5 lists only those excretion values outside
the range encompassed by two standard deviations (Sn) above and below the
means encountered in the group of reference pregnanc·ies. The accepted
range of normality for pregnant women would inevitably be wider than most
reference populations due to the extensive physiological adaptations
associated with pregnancy. Also, for every metabolite there was one or
two of the reference pregnancies with an excretion value outside the
designated mean + 28D. Indeed, the concept of a "normal range of values"
(Sunderman, 1975) is probably too simplistic since absolute health does
not exist and every human being deviates from normality in some respects
(Williams, 1956). Such arguments point out the advantages of repeated
observations on the same individual to define intraindividual variation
(Harris, 1974). Nevertheless, the single 24-h urine collections from
Table 3.5 Acidic metabolite e~cretion in several cases of high-risk pregnancy.
Acidic metabolite excretion compared to normal
pregnancy:
Time of Outside 2 SD above mean (E)
Outcome sample Outside 2 SD below mean (D)
of collection M.U. Relative
pregnancy (weeks) Description of pregnancy value amount/24 h E or D Possible peak identity
Survival Maternal hypothyroidism, 12.15 178 E Methylmalonic acid
of child 26 compensated by Eltroxin S-Hydroxyisovaleric acid
0.1 mg; low serum
vitamin B12 13.68 232 D 4-Deoxytetronic acids
24 Maternal Crohn~s disease 13.68 221 D 4-Deoxytetronic acids
27 Maternal diabetes mellitus 12.27 179 E Benzoic acid I
......
since 10 years of age, ......0
compensated by Toronto I
and NPH insulin 12.41 182 E Levulinic acid
Death of Normal pregnancy;
child 12 sudden infant death 13.68 140 D 4-Deoxytetronic acids
syndrome at 6 months
of age
Death of Miscarriage (unexplained) a-HydroxY-S-methyl-
fetus 17 at 20 weeks 16.27 925 E glutaric acid or
p-Hydroxyphenylacetic
acid
26 Sudden intrauterine 14.00 207 E Glutaric acid
death (polyhydramnios)
at 36 weeks
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risk pregnancies were compared to the categories of normal pregnancy.
Three successful pregnancies were complicated by maternal disease
(hypothyroidism, Crohn's disease, and diabetes mellitus). The woman
with hypothyroidism compensated by dietary thyroid powder also had low
serum vitamin B12 • Concentrations of vitamin B12 are decreased in
maternal serum in normal pregnancy, not necessarily indicative of B12
deficiency (Dietary Standard for Canada, 1976, p.36; published by
Health and Welfare Canada). The feeding of thyroid powder may stimulate
food consumption causing an increase in protein intake. This accentuates
vitamin B12 deficiency since metabolism of the branched-chain amino acids
(valine and isoleucine) requires vitamin B12 (Batra et al., 1979).
Vitamin B12 deficiency is characterized by increased excretion of methyl-
malonic acid, a metabolite of the branched-chain amino acids (Gompertz
et al., 1967). Excretion of methylmalonic acid may be the first indicator
of functional deficiency of vitamin BI2 , a more sensitive indicator than
serum vitamin B12 (Higginbottom et al., 1978). The acidic metabolite
peak (MU 12.15) elevated in the pregnancy complicated by maternal hypo-
thyroidism was not identified by mass spectrometry, but it would not be
surprising if the metabolite was methylmalonic acid.
Three pregnancies (maternal hypothyroidism, maternal Crohn's
disease, and the apparently normal pregnancy followed by death of the
child at 6 months of age due to sudden infant death syndrome) were _
characterized by lower than normal levels of the acidic metabolites
corresponding to the 4-deoxytetronic acids. These decreases in excretion
were not attributable to incomplete 24-h collections. (The woman with
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Crohn's disease excreted only 500 mg of creatinine/24 h, but the 24-h
excretion data were corrected to give the equivalent of 1 g of creatinine/
24 h.) Since neither the function nor the metabolism of deoxyaldonic acids
is known (Haraguchi et al., 1982a, 1982b), the significance of the
decreased 4-deoxytetronic acid excretion was obscure. Likewise, slight
elevations in acidic metabolites in the maternal diabetic and in the
pregnancy terminated at 36 weeks due to polyhydramnios mayor may not be
of significance.
Peak 28 (MU 16.27) was greatly elevated in a pregnancy at 17 weeks
which was later terminated by an unexplained miscarriage at 20 weeks (see
Figure 3.5). If peak 28 was exclusively p-hydroxyphenylacetic acid, the
24-h excretion for normal pregnant and nonpregnant women was 31 + 17 mg/24 h
(n=65), while excretion in the risk pregnancy was 210 mg/24 h. Urinary
p-hydroxyphenylacetic acid is derived from p-tyramine which can arise from
dietary tyrosine due to the action of intestinal bacteria (Chalmers et al.,
1979). Normal p-hydroxyphenylacetic acid excretion has been reported as
11.6 + 11.4 mg/24 h (Tocci et al., 1972), 22.4 + 1.5 mg/24 h (Davis and
Boulton, 1981), and 31.3 mg/24 h (Horning et al., 1966). In small-bowel
disease, dietary tyrosine is degraded by intestinal bacteria which are
present due to bacterial overgrowth syndromes (Chalmers et al., 1979).
Elevated urinary p-hydroxyphenylacetic acid (100-1000 mg/24 h) is rare in
the absence of small-bowel disease (Chalmers et al., 1979). The signifi-
cance of the increased amount of peak 28 in the case of unexplained
miscarriage was unknown.
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4. DISCUSSION
4.1 Urinary metabolites in human pregnancy
The urine contains intermediates and end-products from the
myriad metabolic processes occurring in the body. Compounds present
in the urine may reflect the metabolism of the entire organism, as
well as renal metabolism. There are an estimated 500 acidic compounds
in the urine, 200 of whiCh have been characterized (Spiteller and
Spiteller, 1979). Thus, the urinary acid profile is complex, containing
several recognizable components as well as many more components which
are present in smaller quantities.
There was an amazing qualitative uniformity among urine samples
despite the complexity of urine. All urinary acid profiles exhibited
large peaks due to sulfate, phosphate, hippuric acid, citric acid,
and uric acid. These compounds were recognizable landmarks in the
chromatograms, normal adult excretion rates ranging from 0.5 g/24 h
(citric acid, uric acid) to 1.0 g/24 h (sulfate, phosphate, hippuric
acid), (Diem and Lentner, 1970). Several. well-known organic acids
(for example, a-hydroxybutyric acid and phenylacetic acid) could not
be quantified because of their proximity to these large peaks. Peaks
corresponding to several low-molecular-weight acids (lactic acid,
glycolic acid, oxalic acid, succinic acid, erythronic acid, threonic
acid) were also detected in all urine samples. The 24-hour excretion
of these acids rarely exceeded 300 mg. Several acids (benzoic acid,
tartaric acid, salicyluric acid) were encountered less frequently due
to their dietary origin.
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The quantitative variability of organic acid excretion among
individuals was reflected by the wide range of excretion values
encountered for some metabolites. This heterogeneity could be due to
dietary influences and bacterial flora, as well as individual metabolic
differences. Large intraindividual variations can occasionally be
attributed to diet, especially for substances with a known exogenous
origin. Several investigators examined organic acid excretion in
individuals under extreme dietary conditions (low-carbohydrate, high-fat
diet versus high-glucose diet) and observed only minimal changes in the
excretion profiles (Chalmers et al., 1976b). Other investigators
studied excretion patterns of subjects on a uniform diet and observed
highly individualized profiles (Young et al., 1971; Witten et al.,
1973). Thus, undoubtedly the major factor affecting urinary acidic
metabolite excretion is individual metabolic variation. Genetic
constitution affects metabolic reactions and organ function, leading
to an individualized biochemical profile. Genetic differences may be
important determinants of kidney function (Williams, 1956). The
range of excretion values for a given individual would be narrower
than the population range. This argument encourages longitudinal
health surveillance where the subject provides his own base line data
for comparison of biochemical profiles. The present study compared
urinary organic acid excretion by individual pregnant women at two
time periods in gestation, thereby allowing a more controlled
investigation of the effects of pregnancy on organic acid excretion.
The urinary acid profiles obtained for the normal nonpregnant
women agreed well qualitatively with previously published patterns
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(Lawson et al., 1976; Cohn et al., 1978). Unfortunately, quantitative
comparison of the present results with previously published data was
not possible. Other workers analyzed untimed morning urine specimens
and did not calculate GC detector response factors. Thus, the majority
of workers report excretion data as percentages of an internal
standard per mg of urinary creatinine. In contrast, I have chosen to
analyze 24-hour urine specimens and present data in a format which
can be readily converted to mg/24 h or ~mol/24 h.
This thesis contains the first description of urinary organic
acid profiles in pregnancy. Previous inve~tigators have focussed only
on single metabolites which were often quantified by methods less
reliable than the present gas-chromatographic methods. Other workers
have determined maternal urinary methylmalonate levels (most recently
Bakker et al., 1978) in pregnancies at risk for methylmalonic acidemia.
--
Herzberg et ale (1977) claimed that glucaric acid excretion increases
in pregnancy (from 2 mg/g creatinine in nonpregnant women to 5 mg/g
creatinine by the second trimester), supposedly reflecting the induction
of hepatic enzymes. In contrast, the present data showed no increase
in glucaric acid excretion in pregnancy. Herzberg!:! ale (1977)
quantified glucaric acid by measuring the inhibition of S-glucuronidase,
an enzyme which is powerfully inhibited by the lactone of glucaric
acid (Fishman, 1967). This indirect method of measuring glucaric acid
output may be influenced by the presence of other B-glucuronidase
inhibitors in urine, for example, sulfate ions (Graef ~ al., 1977)
as well as citric acid and gluconic acid (Roy, 1970). Additional
compounds excreted in increased amounts in pregnancy urine may add to
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the complexity of this enzyme inhibition assay. For example, other
polyhydraxycarboxylic acids (the aldonic and deoxyaldonic acids) could
conceivably be additional B-glucuronidase inhibitors.
The obvious multicomponent nature of unsymmetric peaks in the
urinary acid chromatograms stresses the need for caution when interpreting
the data. Thus, until further mass spectrometric analyses are performed,
discussion must be restricted to those peaks of interest which have
been unequivocally identified (lactic acid, glycolic acid, erythronic
acid).
Urinary lactic acid levels tended to increase with pregnancy,
but excretion was rather sporadic. The wide range of excretion values
emphasized the inadequacy of expressing the data as a mean + SD. Lactate
excretion in the nonpregnant women was somewhat lower than values
reported by other workers (Judge and Van Eys, 1962; Elliot and Ribeiro,
1972), as shown in Table 4.1. These workers used the colorimetric
method of Barker and Summerson (1941) which involves the conversion
of lactic acid to acetaldehyde followed by color production with
p-hydroxyphenyl. Lower values would be expected with the present gas-
chromatographic method which is a more specific and direct measure of
lactic acid. While lactate excretion never exceeded 100 mg/24 h in
the nonpregnant women, values over 350 mg/24 h were encountered in
pregnancy. Lactic acid excretion is increased with severe exercise
(Miller and M2ller, 1949). The lethargy and reduced energy expenditure
characteristic of pregnancy {Hytten, 1972) argue against the increased
lactate excretion of pregnancy being due to increased physical activity.
Normally, lactate is almost completely reabsorbed by the kidney tubules
Table 4.1 Urinary lactic acid excretion in normal subjects.
Lactic acid excretion (mg/24 h) Method
Subjects n Mean + SD Range (Reference)
Male and female 20 41 + 14 22 - 82 Colorimetric (Judge and
Van Eys, 1962)
Male 30 46 + 26 15 - 153 } Colorimetric (Elliot and
Female 17 46 + 17 22 - 96 Ribeiro, 1972) I
.....
.....
Female 15 22 + 22 5 - 75 coI
Pregnant, l2~ - l5~ weeks 25 65 + 79 8 - 366 Gas chromatography(present work)
Pregnant, 24~ - 27~ weeks 25 118 + 92 18 - 378
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when blood lactate concentrations are below the renal threshold of
60 mg/dl (Miller and Miller, 1949). Healthy subjects with renal
glycosuria have normal blood lactate concentrations but they excrete
lactate in their urine at levels about three times greater than that
of normal subjects (Anderson and Mazza, 1963). Evidence such as this
has supported the idea that lactate and glucose excretion are related.
Glucose, bicarbonate, acetoacetate, phosphate, and several amino acids
(alanine~ valine, glycine, and tryptophan) are known to inhibit each
bther in renal transport studies (Drummond and Michael, 1964). Recent
evidence suggests that such substances do not share a common renal
transport carrier, but instead may compete for a common energy source
(Short and Rosenberg, 1979). Glycosuria occurs in about 50% of all
pregnant women and is very episodic in nature (Lind, 1975). As well,
several amino acids (glycine, histidine, threonine, serine, and alanine)
are excreted in excessive amounts during pregnancy (Hytten and Cheyne,
1972). Thus, the renal excretion of lactate in pregnancy may be
governed by the same unknown factors which lead to the glycosuria and
aminoaciduria of pregnancy.
Lactic acid is by far the dominant acidic constituent in aumiotic
fluid, present at 50 - 100 mg/dl (Hagenfeldt and Hagenfeldt, 1972;
Nicholls et al., 1976; Wilkinson et al., 1979). The fetus is a
-- --
consumer rather than a producer of lactate, although the precise
fate of lactate in the fetus is unknown (Battaglia and Meschia, 1978).
Lactate is supplied by the placenta to the fetus in large amounts
(Burd et al., 1975). The placenta deposits lactate into both the fetal
and maternal circulations (Milley and Simmons, 1979; Char and Creasy,
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1976). The etiology of placental lactate production is unknown.
Other tissues with high rates of lactate production (tumor, intestinal
mucosa, kidney tubule) are also actively involved in transport
(Milley and Simmons, 1979). While increased maternal lactate excretion
may reflect normal placental function, the wide range of excretion
values encountered would probably preclude the use of this urinary
organic acid as a reliable indicator of pregnancy status.
Although lactic acid excretion was sporadic, the excretion of
glycolic acid, the tentatively identified 4-deoxytetronic acids, and
erythronic acid increased simultaneously (see Table 3.4.3.6, page 95).
These three acidic metabolite peaks were consistently increased in the
pregnant women, as seen by the small standard deviations of mean
excretion values (see Table 3.4.3.5, page 94). They were excreted in
approximately equimolar quantities within each group of women studied.
The consistent, simultaneous increase in excretion of these metabolites
points to their possible common origin.
There was excellent analytical precision for the determination
of the four noteworthy urinary acidic metabolites (lactic acid, glycolic
acid, the 4-deoxytetronic acids, and erythronic acid) as shown in
Table 3.4.3.7, page 103. Thus, it is unlikely that these peaks would be
formed due to random chemical degradation of compounds during the organic
acid extraction procedure. The most extensive chemical and chroma~o­
graphic studies of the aldonic and deoxyaldonic acids have been done by
Petersson (1970, 1974, 1977). These acids may be formed by the action
of alkali on various aldoses and deoxyaldoses CMorrison and Perry, 1966;
Verhaar and De Wilt, 1969}. Roesel et al.(1979} reported the production
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of lactic acid (otherwise named 3-deoxyg1yceric acid) from glucose by
alkaline hydrolysis. The oxidation of maltose with 0.05 M sodium
hydroxide gives 2-deoxytetronic acid (Fell et a1., 1975). Thus,
alkaline conditions should probably be avoided if artifactual aldonic
acid formation is not to occur. This has, however, been disputed by
Thompson et. al.(1975) who used a barium hydroxide sample pretreatment
and observed no artifacts. Glucose can apparently be leached from the
dextran-based DEAE-Sephadex resin (Brewer et a1., 1974). The Sephadex
resin was initially washed with 2.0 M pyridinium acetate in the present
method, while the buffer used for elution of the organic acid fraction
was 1.5 M pyridinium acetate. Also, no extraneous peaks were observed
with extractions of distilled water. The present organic acid extraction
procedure did not involve extreme alkaline conditions. Conversely, no
1actones of hydroxy acids were observed, such as may be formed under
acidic conditions (Szafranek ~ a1., 1974).
Neither the function nor the metabolism of aldonic and deoxy-
aldonic acids is known (Haraguchi et a1., 1982a, 1982b; Niwa ~ a1.,
1981). These acids were only a few years ago identified as regular
constituents of urine. The urine of adults contains large amounts of
erythronic acid, threonic acid, and 4-deoxythreonic acid. Moderate
amounts of 4-deoxyerythronic acid and 2-deoxytetronic acid are found,
while only trace amounts of 3-deoxytetronic acid are normally obse~ed
(Thompson et a1., 1975). Since the appearance of these compounds is
little affected by large dietary alterations, they are probably of
endogenous origin. The oxidation of erythrose, a metabolite of glucose,
probably gives rise to erythronic acid (Lawson et a1., 1976). The
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excretion of 2-deoxytetronic acid appears to be greatly increased by a
high-glucose diet (Chalmers et al., 1976b; Tracey et al., 1981). The
metabolism of 4-hydroxybutyric acid may produce 2-deoxytetronic acid
as "an intermediate (Niwa et al., 1982a; Walkenstein et al., 1964).
Other 2-deoxyaldonic acids may be derived from 2-deoxyribose of deoxy-
ribonucleic acid (Haraguchi et al., 1982a; Truscott et al., 1979a).
While the mechanisms are not yet known, alterations in glucose
metabolism appear to influence the aldonic and deoxyaldonic acids.
Glycolic acid increases simultaneously with several deoxyaldonic acids
in rat heart muscle after a reduction in coronary blood flow (Haraguchi
~ al., 1982b). The glycolic acid is presumably formed from glyoxylic
acid (Haraguchi ~ al., 1982b). It may be no coincidence that cleavage
of the glucose molecule between the second and third carbon atoms would
produce a 2-carbon fragment resembling glyoxylic acid and a 4-carbon
fragment resembling erythritol. The 2-carbon fragment could lead to
glycolic acid, while the 4-carbon fragment could lead to erythronic
acid. Erythritol, a compound used as a coronary vasodilator in humans
(Windholz, 1976), is also the normal 4-carbon sugar alcohol found in
the urine of newborn infants (Horning and Horning, 1970). Cleavage of
aldoses such as glucose would be analogous to the metabolism of ascorbic
acid via threonic acid and oxalic acid (Tolbert et al., 1967; Hellman
and Burns, 1958). Placenta, lens, and seminal vesicles are the only
tissues known to contain aldose reductase (Van Heyningen, 1959). Thus,
it is not known whether the presently observed increases in urinary
excretion of aldonic and deoxyaldonic acids reflect fetal, placental,
or maternal metabolism. This account of their unmistakable increase
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in excretion with normal pregnancy poses exciting questions as to their
reliability as indicators of pregnancy status.
4.2 Acceptability of the present methods
The present organic acid and steroid extraction methods were
chosen because they offered the simplest, most reproducible, and most
general extraction of each group of compounds. These multicomponent
extractions did not optimize the recovery of all components such as
could be achieved with methods developed for the analysis of single
compounds, but the overall recoveries were generally good.
The majority of workers use the Amberlite-XAD adsorption
procedure of Bradlow (1968) for urinary steroid extractions (Vrbanac
~ al., 1982; Shackleton and Whitney, 1980). The present method
performed well in the extraction of steroid conjugates from standard
solutions. Due to the complexity of the urinary steroid fraction,
however, the gas-chromatographic profiles of urine"samples from
pregnant women were difficult to interpret. High-resolution capillary
columns would be needed in the gas-chromatographic analysis to
accurately quantify the individual steroid metabolites. The present
method, however, could be considered semi-quantitative since the trend
of increasing steroid output in pregnancy was clearly visible (personal
observation, data not presented). Indeed, when large deviations from the
normal pattern have to be confirmed, no quantitative method is required.
A minority of workers use DEAE-Sephadex anion-exchange extraction
of organic acids because the quicker solvent extraction methods have
gained wide acceptance. The majority of workers use a diethyl ether-
ethyl acetate extraction procedure (Knights et al., 1975; Fitch et al.,
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1979; Tanaka et al., 1980b) which discriminates against highly water-
soluble acids. Other workers have used DEAE-Sephadex extraction
procedures preceded by a barium hydroxide precipitation of the inorganic
sulfate and phosphate (Thompson and Markey, 1975; Thompson et al., 1977;
Gates et al., 1978) which also precipitates many organic acids. The
present straightforward DEAE-Sephadex method allowed the quantitative
extraction of many organic acids, including the noteworthy polyhydroxy-
carboxylic acids (the aldonic and deoxyaldonic acids) which form 30-35%
of total organic acid excretion (Chalmers et al., 1976a). These acids
would be poorly recovered by solvent extraction techniques, and partially
coprecipitated by barium hydroxide sample pretreatment. Thus, the present
method allows a truly quantitative extraction of many urinary organic
acids. In addition, the lyophilization, methanol transfer, and vortex-
evaporation steps in the present procedure lead to more reproducible
recoveries (Chalmers and Watts, 1972c) as well as convenience in perform-
ing the extractions. Recent publications have emphasized the superiority
of anion-exchange extraction techniques compared to other organic acid
extraction methods (Boujet ~ al., 1982; Rehman et al., 1982). High-
resolution capillary columns would also increase the accuracy of quanti-
tative organic acid analysis, but with hundreds of acidic metabolites
potentially present in urine (Spiteller and Spiteller, 1979), even
capillary columns could not be expected to resolve all components.
The present gas-chromatographic methods allow simultaneous
organic acid-steroid profiling. The simple derivatization procedures
involve oximation and silylation with no sample transfers or sample
clean-up before gas chromatography. The low-molecular-weight organic
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acids elute before the tricosane internal standard, while the high-
molecular-weight steroids elute after tricosane. Thus, quantitative
data pertaining to gas-chromatographic behavior of compounds (retention
data; detector response factors) can be acquired simultaneously for
organic acids and steroids. When examining biological fluids it may
not be advisable to directly combine the organic acid and steroid
fractions since unexpected cross-contamination of peaks could possibly
occur. If the two fractions are extracted and derivatized in parallel,
however, they can be analyzed sequentially on the same gas chromatograph
under the same instrumental conditions. This is feasible where an
automatic sample injector can operate 24 hours a day. Thus, the actual
sample extraction procedures would be the limiting factors regarding
speed of sample analysis.
The present methods were highly reliable (Buttner et al., 1975,
1976). The sample purification methods produced no artifacts. Neither
did these methods cause destruction or chemical modification of
compounds. Derivative formation was quantitatively reproducible. As
little as 1-2 mg of compound in a 24-hour urine sample could be
quantified, depending on the extraction efficiency and detector response
characteristics of the compound. The recovery of compounds from standard
solutions was highly accurate, approximating 100% in several instances.
There was good analytical precision for the determination of organic
acids in urine, as evidenced by the small coefficient of variation of
duplicate determinations from their means. The present methods were
also practical. If samples were extracted in 20-sample batches,
approximately 1 day was needed for organic acid analysis, while 1~ days
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were needed for steroid analysis. The methods can thus be used for a
large number of assays where urgency of analysis is a secondary
consideration. The resins employed for extraction (DEAE-Sephadex and
Amberlite XAD-2) are reusable after appropriate washing procedures.
Operation of the gas chromatograph was dependable once the problems
of detector linearity and molecular sieve reactivation were corrected.
Various means were employed to identify unknown peaks when
they occurred in the chromatograms. The methylene unit value was first
determined, thus ruling out possible compound identities. Careful
scrutiny was given to extractions of distilled water, thereby excluding
the possibility of artifacts. Various oximating agents were employed,
thus identifying keto compounds. The history of the urine specimen was
investigated by reviewing previous dietary and drug intake. Tentative
peak identifications were made on the basis of literature values
published by other workers for compounds which were not commercially
available. Finally, unequivocal confirmation of peak identity was
attained by mass spectral analysis.
Thus, the. application of these highly acceptable methods
produced reference profiles of urinary metabolites in human pregnancy.
These methods could be applied directly to other protein-free fluids,
such as amniotic fluid (Ng et a1., 1982; Nicholls et a1., 1978),
newborn urine (Bjorkman et a1., 1976), and cerebrospinal fluid (Malcolm
and Leonards, 1976). Recent improvements in ultrafiltration procedures
(Issachar and Sweeley, 1981) would allow the present methods to be
applied to plasma (Issachar et a1., 1982) and other protein-containing
body fluids.
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Appendix A
UtaVERSlIY Oli SASKATCHEWAN
. PRINCIPAL'S ADVISORY COMMITTEE ON ETIIICS IN IIUHAN EXPERHtENTATION
Dr. I.S. Mendelson (EcI78-3)
"Early Diagnosis of Human Growth and Development Disorders"Your Project entitled _
has been approved by the Committee.
1. Therefore you are free to proceed with the following conditions:
2. Any significant changes of protocol should be reported to me for the
Committee's consideration in advance of its implementation.
3.- If you are applying for funds for this projec~ to-any of the following
agencies. the required form is being completed by this office and forwarded
to the agency with a copy enclosed herewith for your record:
- National Institute of Health
- Medical Research Council
- Canadian Heart Foundation
Sincerely.
1W:paw
~vj~~
Dr. T.W. Wilson, Chairman
Principal's Advisory Committee
on Ethics in Human Experimentation
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Appendix B
Informed Consent Form
A Prenatal Study into the Prevention of Disorders in Child Gro~h and Development
The Alvin Buckwold Centre Department of Pediatrics, University Hospital, Saskatoon would like to
collect specimens from you during your pregnancy for the expressed purpose of research~
prevention of disorders in gro~h and development. We would like to establish a biochemical
profile of trace elements 'or. minerals (zinc, copper, iron, manganese, ,chromium), urinary
metabolites, hormones and vitamins. This research project may be of value to future generations
but if abnormal biochemical values are found in your specimen. your doctor will promptly be
informed. The specimens will be collected in the morning by our staff at your home with as
little inconvenience to the doctor and yourself as possibl~.
The following samples are required if you agree to participate in the project:
a) End of 3rd month of pregnancy - fastin~ blood samples
- a 24 hr. urine collection
b) End of 6th month of pregnancy - fasting blood samples
- a 24 hr. urine collection
c) At the time of birth - a tube of maternal blood
- a tube of cord blood
d) Approximately 6 weeks post partus - a tube of fasting blood & a 24 hr. urine collection
We also request your permission to correlate the biochemical profile with the clinical assess-
ment made by your doctors of your pregnancy and your newborn baby. Strict confidentiality
will be maintained.
You are quite free to withdraw at any time from this study.
If you do not agree to participate in the study. this will not effect in any way the quality
of medical care from your doctors.
If more information is required or you wish to visit the Alvin Buckwold Centre and its
Laboratory, we will be glad to arrange a visit at a suitable time (343-5901). We thank you
for considering our proposal and whatever is your decision. we wish you the best of success.
Respectfully yours,
1.5. HendelsoD, Ph.D,
Assistant Professor of Pediatrics
Lecturer in Physiology
W.A. Zaleski, M.D., M.R.C.Psych., f.R.C.P.(C)
Professor. Department of Pediatrics
Bome, 5115P' _
Doctor's 5ignature~ ---
Slgnature~ _
I agree to participate in the Alvin Buckwold Centre's prenatal study into the prevention of
disorders in child growth and development.
Doctor's name _
Patient' s name _
Address:..- ...;,;. _
Telephone Number: Work _
Return to:
Alvin Buckwold Centre, Department of Pediatrics To Be Filled in by Doctor:
Room 4S, EIlts Hall Last Menstral Period
University Hospital, Saskatoon, Saskatchewan, --------
S7N 0W8 Expected Date of
Confinement _
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Appendix C
Dear Participant,
Thank you for participating in our study into the prevention of' disorders
of child growth and development.
A member of our laboratory staff will be contacting you shortly regarding
your preparation for the collection of specimens as follows:
(1) The night before the first morning visit, you must not eat or drink,
except for water, after 12:00 midnight until our technologist arrives
early in the morning.
(2) When our technologist arrives, she would like to collect a morning
urine specimen, at which time the 24-hour urine collection will begin.
The 24-hour collection will be completed when you void at exactly the
same time the next day. .
(3) A venous blood sample will also be taken.
(4) Arrangements will be made to pick up the 24-hour urine specimen the
following day. If you are passing by the University Hospital, it can
be deposited at Room 45, ground floor, Ellis Hall, Alvin Buckwold Centre.
Please retain this letter for our next visit in approximately 3 months.
If at any time you wish to withdraw, please feel free to inform us. If you
have any questions or suggestions, we would like to hear them. We thank you
again for your participation.
Our best wishes,
1.5. Mendelson, Ph.D.
Assistant ~rofessor
Department of Pediatrics
W.A. Zaleski, M.D., M.R.C.Psych., F.R.C.P.(C)
Professor, Department of Pediatrics
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- Appendix D
DIET RECALL
Name: -..:.Date: _
From memory, please list as accurately as possible all food and beverages
(and the approximate quantity of each) consumed in the previous 24 hours.
Breakfast
Medications
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-Appendix E
24-HOUR DIET DIARY
Name: --'Date:, _
Your present weight : ~Height : _
In the following chart, please record all substances eaten for the duration of
the 24-hour urine collection. This includes all food and beverages and the
approximate quantity of each.
Time of meal (or snack)
Example: 8:00 a.m.
9:30 a.m.
Food or beverage
8 oz. milk
1 banana
~
11111\
Saskatchewan
Heallh
Hospital Services
Plan
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Appendix F
Prenatal Record
i IAge Date 01 Sinh
I Name
i Telephone No.
IAddress
; Date 0 ..orsl VISit
'Father of Chnd
ramjjy PhysiCian Iuosletneian 't"eOl8tncl81l
r Obstetrical History InclUding Abortions:
10,;,. j:)l'l(e 'Jf I(h,r Pre,; iH,,:,urs 0' 'T'\I'Pf" c! Co""tOilCatlOf'\S Molh@r ?inC ?I !'1l<1nt Cfhld
, C'}nN'loPmef'l' lWks utiour Deltvt!:". Se. eirtn WI Pres~
! ! I i ! II I
! 1
t
i
I
!
I Past illnesses: No Yes Specify , Family history: No Yes SpecifyI,
Renal .- -i Diabetes - ~.Cardiac - .. .- 0-I .- Cardiac - -infections .. ~ ....
-
Flubella - - HypertenSIOn - '....
- TuberCUlosis - -Venereal - -
Twins .-- -Allergtes - .- . -Malfonnations .- -Operations - -
,
.. .. Mental Retardalion - -I Transfusions - - .-
-
- Other I· ei Other - .. -"
• Menstrual history: History of present prllflnancr- Specify Current medications
I Cycle DuratlOl1! l.MP Normal - Abnormal
Method of contra~ption: Nausea. Vomiting No Yes .
Bleeding No Yes - Date:
Fever No Yes Date:
Dale 01 Radialion No
_.
Yes
.. Date:
Discontinuance Smoking No Yes Amount:
Pre·Preg. Weight IHe'llht Drug Use No:: Yes Identify:
Nutrition Poor GoOd -
Ellamination Date
General Condilion: Breasts:
Head & Neck: Abdomen:
Lymph NOdes: Spine:
Heart: Umbs:
Lungs: Pelvic Examination:
1 Fetal Risk Scorinil "A" Baseline Da. (Mallimum SccnI Is 3) PreviouS ObstetriCal History
1 -. Rh iso -Immunized Mother 2 -Age 35 +
-40 + 2 -. Pos. HiStory 01 ErythroblastosiS 3 - Abortion
-"
_.
I ParaO I ~ Stilfbitth -
I 6+ 2 · Neonatal Death -
-
0-
, inlervalless lhan 2 years I - SurvivIng Premature Inlanl -
ObeSity 200 lb. + 1 · Antepartum HemorrhaOe -
Diabetes - Mild. Moderate 2 · . Toxemia
~
Severe 3 - Mid-Forceps DehYer'( -
Chromc Renal DIsease I - Cesanan Section -
wilh Dimirnshed Renal Function 3
.. Major Congenital Anomaly -IPre-Exisllng Hypertension Baby 10 Ibs. + '0
.- D -140 ... 90 ... , Total Score Part "A" One Instance 01 Above 1 .-
160+ 110+ 2 Two or More Instances 01 Above 2
.
Doctor's Chart
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Appendix F
FullTerm Prematures I Abortions Uve Births Grav. IE.D.C IDale 01 """ken"",Deliveries 1500 grams or less Surviving Dying before
7 days 7 days
V.D.R.L ABOG_I RH IFather of Child Rubella Titre Pap smear Notations lor DeliveryRH Genotype
I
Fetal Risk SCoring "S" Present Pregnancy (Maximum SCore is 3) Other Investigations
- Date IType IFindingsI•.g. Hydramnips 21 Toxemia Mild· Moderate 1 ~3 Severe 3
-
Bleeding. before 20 weeks Hydramnios (Single Fetus) 3 -~ -Alone 1
-
With Pain 2 ~ 2 ' , I- Multiple Pregnancy -
Bleeding, after 20 weeks
~ Abnormal Glucose Tolerance 1 -
I
Ceased 1
-
-
ContinUes 2 -
-
-With Pain 3 - Decreasing Insulin Requirement 3 :...J
-
With Hypotension 3 -
-
-Maternal Diabetic Acidosis 3
-Spontaneous Premature
-Rupture of Membranes 1
- Maternal Pyrexia 1 -
Latent Period 24 hr. + 2 - -
-
Anemia 8 to' 10 gms. 1 - Pyrexia + FHR Greater Than 160 . 2 ::::
.-
Less than 8 gms. 2 -
- RH Negative
No Prenatal Care 2 - With Antibody ntre 2 -
- '- I1 to 3 Prenatal ViSits 1 - With Amniotic Fluid Liley Zone III 3 -~
C Gestational Age (At time of scoring) 36·37 Wks. 1
-28 Wks. or Under 4 -- 38·41 Wks. 0 -
--
-29·32 Wks. 3 - 42 Wks. 1 -...
-
33·35 Wks. 2 - 43 Wks. or More 2 -
-
Prenatal ! Fetal Risk SCore (Maximum is 10) Evaluation Sumrriary
Classes Yes - No :- I .._- ... Seore (nO 2 Low Risk
Father IA. Baseline [===:J + B + C = Total Seore Score 3 to 6 Moderate Risk
For Case Room Yes -. No - Data' Score> 6 High Risk
Our of IFunaus I P'ese<1l I : I
ledemll~ i~isk IDlIte P'e'g In '" If and F H I e"gage· BP IWT HB Medications and Remarlls !Q",,!~;rn\VPekS W~tl;.S i POSt IIon i ~afe i m~"t I I Alb iSug , Score lOr.;
! I I
I
I I
,
i iI II i I i I I
I ! I I· i !
I
I I I
!
I I I! II ! I ! I
I I i ! ! i i i I iI ! i ! , I
i I ! I
I : II I II I I I I
I I I 1 I i j i TI !I I i i
i I I i I iI I i I I ! I
; i ! ! i iI I t I I I II
I
I I I i II!
J I I ! I !i I
I , I I
!
, I
I ! r I _Ii . I
I ! !
I
i I j , i \
i I I i I I II ,! I
I I I 1 ; II
\
I I \ I I! I
-151-
Appendix G
University Hospital, Saskatoon
INFANT DISCHARGE FORM
ANTEPARTUM:
Maternal Age
Blood Type
Antibodies: LMNP 0
Yesn NoD
spec'I1y : Due 0
Grav.
Para.
Last HGB Gestn. 0
At Del.
Abort.
ABNORMALITIES OF PREVIOUS PREGNANCIES:
Specify:
Antepartum Status
YesO NOD
ABNORMALITIES OF PR...~IOUS INFANTS: Yes 0 NOD
Specify:
COMPLICATIONS OF THIS PREGNANCY: Specify:
None 0 . Toxemia 0 Heart 0
Bleeding 0 Diabetes 0 Other 0
LABOR & DELIVERY: Fetal Distress: Yes 0 No 0
Sponte 0 Specify Indications:
Operative 0
COMPLICATIONS: Spec1fy:
(Include Forceps)
CONDITION 1 &5 Min. AFTER BIRTH (Grade as O,l,or 2) RESUSCITATION: None 0
OXygen Only 0 I.P.P.B. ~ KaSkO
I.P.P.B. & E.N.T.
Duration: to Kins.
Boy 0 Alive 0 Antiseptic Eye Drops 0
Girl 0 Stillborn 0 Vit.KlD
s.G~A.D H B G Blood Type
q ---
A.G.A.O
L.G.A.O
Wks.
First Breath Sees.
First Cry ~cs.
Sustained Respirations
Sees.
ASPHYXIA: None 0 Mad·O
severeD
Specify Gest. AgeWeight __ G Prete%1ll 0
Lenqth em Full Term 8·Head --em
Post Term
Tone
Color
Respirations
Response
Heart Rate
Apgar
Kidneys 0
umbilicus 0
Inquinal Or£ices0
Genitalia0
RectuaO
Extremities 0
Hips (Abduction) 0
Skin0
SUCkinqo
RootinqD
MoroO
bISck4RGE:
Autopsy:
Alive 0 Died0
Yeso NOD
Weiqht _G.
Lenc;th _ OIl.
Bead CDl.
Sicmature1
Feedin9s &/or MedicatioDS 1
